<!DOCTYPE html>
<html class="client-nojs" lang="en" dir="ltr">
<head>
<meta charset="UTF-8"/>
<title>Glaucoma Secondary to Intraocular Tumors - EyeWiki</title>
<script>document.documentElement.className="client-js";RLCONF={"wgBreakFrames":!1,"wgSeparatorTransformTable":["",""],"wgDigitTransformTable":["",""],"wgDefaultDateFormat":"mdy","wgMonthNames":["","January","February","March","April","May","June","July","August","September","October","November","December"],"wgRequestId":"ZAVjVyDQPk8S6VBAOJtdFQAAAAg","wgCSPNonce":!1,"wgCanonicalNamespace":"","wgCanonicalSpecialPageName":!1,"wgNamespaceNumber":0,"wgPageName":"Glaucoma_Secondary_to_Intraocular_Tumors","wgTitle":"Glaucoma Secondary to Intraocular Tumors","wgCurRevisionId":86663,"wgRevisionId":86663,"wgArticleId":3361,"wgIsArticle":!0,"wgIsRedirect":!1,"wgAction":"view","wgUserName":null,"wgUserGroups":["*"],"wgCategories":["Articles","Glaucoma","Oncology/Pathology"],"wgPageContentLanguage":"en","wgPageContentModel":"wikitext","wgRelevantPageName":"Glaucoma_Secondary_to_Intraocular_Tumors","wgRelevantArticleId":3361,"wgIsProbablyEditable":!1,"wgRelevantPageIsProbablyEditable":!1
,"wgRestrictionEdit":[],"wgRestrictionMove":[],"sdgDownArrowImage":"/w/extensions/SemanticDrilldown/skins/down-arrow.png","sdgRightArrowImage":"/w/extensions/SemanticDrilldown/skins/right-arrow.png","wgCiteDrawerEnableDesktop":!1,"wgCiteDrawerEnableMobile":!0,"wgCiteDrawerTheme":"dark","wgPageFormsTargetName":null,"wgPageFormsAutocompleteValues":[],"wgPageFormsAutocompleteOnAllChars":!1,"wgPageFormsFieldProperties":[],"wgPageFormsCargoFields":[],"wgPageFormsDependentFields":[],"wgPageFormsCalendarValues":[],"wgPageFormsCalendarParams":[],"wgPageFormsCalendarHTML":null,"wgPageFormsGridValues":[],"wgPageFormsGridParams":[],"wgPageFormsContLangYes":null,"wgPageFormsContLangNo":null,"wgPageFormsContLangMonths":[],"wgPageFormsHeightForMinimizingInstances":800,"wgPageFormsShowOnSelect":[],"wgPageFormsScriptPath":"/w/extensions/PageForms","edgValues":[],"wgPageFormsEDSettings":null,"wgAmericanDates":!0,"wgVisualEditor":{"pageLanguageCode":"en","pageLanguageDir":"ltr",
"pageVariantFallbacks":"en"},"srfFilteredConfig":null,"wgEditSubmitButtonLabelPublish":!1};RLSTATE={"site.styles":"ready","noscript":"ready","user.styles":"ready","user":"ready","user.options":"loading","ext.cite.styles":"ready","mediawiki.ui.button":"ready","skins.chameleon":"ready","zzz.ext.bootstrap.styles":"ready","mediawiki.toc.styles":"ready","ext.CookieWarning.styles":"ready","oojs-ui-core.styles":"ready","oojs-ui.styles.indicators":"ready","mediawiki.widgets.styles":"ready","oojs-ui-core.icons":"ready","ext.visualEditor.desktopArticleTarget.noscript":"ready","ext.srf.styles":"ready","ext.smw.style":"ready","ext.smw.tooltip.styles":"ready"};RLPAGEMODULES=["ext.smw.style","ext.smw.tooltips","ext.cite.ux-enhancements","smw.entityexaminer","site","mediawiki.page.startup","mediawiki.page.ready","mediawiki.toc","ext.citedrawer.main","ext.CookieWarning","ext.visualEditor.desktopArticleTarget.init","ext.visualEditor.targetLoader","ext.eyeWiki","ext.eyeWiki.slideshow","sentry.init",
"ext.bootstrap.scripts"];</script>
<script>(RLQ=window.RLQ||[]).push(function(){mw.loader.implement("user.options@1hzgi",function($,jQuery,require,module){/*@nomin*/mw.user.tokens.set({"patrolToken":"+\\","watchToken":"+\\","csrfToken":"+\\"});
});});</script>
<link rel="stylesheet" href="/w/load.php?lang=en&amp;modules=ext.CookieWarning.styles%7Cext.cite.styles%7Cext.visualEditor.desktopArticleTarget.noscript%7Cmediawiki.toc.styles%7Cmediawiki.ui.button%7Cmediawiki.widgets.styles%7Coojs-ui-core.icons%2Cstyles%7Coojs-ui.styles.indicators%7Cskins.chameleon%7Czzz.ext.bootstrap.styles&amp;only=styles&amp;skin=chameleon"/>
<link rel="stylesheet" href="/w/load.php?lang=en&amp;modules=ext.smw.style%7Cext.smw.tooltip.styles&amp;only=styles&amp;skin=chameleon"/>
<link rel="stylesheet" href="/w/load.php?lang=en&amp;modules=ext.srf.styles&amp;only=styles&amp;skin=chameleon"/>
<script async="" src="/w/load.php?lang=en&amp;modules=startup&amp;only=scripts&amp;raw=1&amp;skin=chameleon"></script>
<style>#mw-indicator-mw-helplink {display:none;}</style>
<meta name="ResourceLoaderDynamicStyles" content=""/>
<link rel="stylesheet" href="/w/load.php?lang=en&amp;modules=site.styles&amp;only=styles&amp;skin=chameleon"/>
<meta name="generator" content="MediaWiki 1.35.8"/>
<meta name="description" content="Ocular tumors or systemic malignancies that spread to the eye can lead to intraocular pressure elevation through many different mechanisms. If not diagnosed early, the tumor’s effect on eye pressure or spread of the tumor itself can be sight or life threatening. In patients with highly asymmetric glaucoma or eye pressure elevation that is resistant to standard medical therapy, a thorough history and ocular exam (including pertinent imaging) should be performed to rule out intraocular malignancies."/>
<meta name="date" content="2022-11-16"/>
<meta name="WT.seg_1" content="0"/>
<meta name="google-site-verification" content="mtQvMIGqpWB4oyYM5mux15MHU-3qWI0bWtyRa2b5rlk"/>
<meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"/>
<link rel="alternate" type="application/rdf+xml" title="Glaucoma Secondary to Intraocular Tumors" href="/w/index.php?title=Special:ExportRDF/Glaucoma_Secondary_to_Intraocular_Tumors&amp;xmlmime=rdf"/>
<link rel="shortcut icon" href="/w/extensions/EyeWiki/favicons/favicon.ico"/>
<link rel="search" type="application/opensearchdescription+xml" href="/w/opensearch_desc.php" title="EyeWiki (en)"/>
<link rel="EditURI" type="application/rsd+xml" href="https://eyewiki.org/w/api.php?action=rsd"/>
<link rel="preconnect" href="https://fonts.gstatic.com">
<link href="https://fonts.googleapis.com/css2?family=Lato:ital,wght@0,400;0,700;1,400&display=swap" rel="stylesheet">
<!-- Favicons MEYE-108 -->
<link rel="apple-touch-icon" sizes="120x120" href="/w/extensions/EyeWiki/favicons/apple-touch-icon.png">
<link rel="icon" type="image/png" sizes="32x32" href="/w/extensions/EyeWiki/favicons/favicon-32x32.png">
<link rel="icon" type="image/png" sizes="16x16" href="/w/extensions/EyeWiki/favicons/favicon-16x16.png">
<link rel="manifest" href="/w/extensions/EyeWiki/favicons/site.webmanifest">
<link rel="mask-icon" href="/w/extensions/EyeWiki/favicons/safari-pinned-tab.svg" color="#603cba">
<link rel="shortcut icon" href="/w/extensions/EyeWiki/favicons/favicon.ico">
<meta name="msapplication-TileColor" content="#603cba">
<meta name="msapplication-config" content="/w/extensions/EyeWiki/favicons/browserconfig.xml">
<meta name="theme-color" content="#ffffff">
<script> window.interdeal = { "sitekey": "81c701489fb8bb4ab90ca1cb0931f9c5", "Position": "Left", "Menulang": "EN", "domains": { "js": "https://cdn.equalweb.com/", "acc": "https://access.equalweb.com/" }, "btnStyle": { "vPosition": [ "80%", null ], "scale": [ "0.8", "0.8" ], "color": { "main": "#1876c9" }, "icon": { "type": 1, "outline": false } } }; (function(doc, head, body){ var coreCall = doc.createElement('script'); coreCall.src = 'https://cdn.equalweb.com/core/4.3.8/accessibility.js'; coreCall.defer = true; coreCall.integrity = 'sha512-u6i35wNTfRZXp0KDwSb3TntaIKI2ItCt/H/KcYIsBeVbaVMerEQLBnU5/ztfBg9aSW1gg7AN4CqCu9a455jkUg=='; coreCall.crossOrigin = 'anonymous'; coreCall.setAttribute('data-cfasync', true ); body? body.appendChild(coreCall) : head.appendChild(coreCall); })(document, document.head, document.body); </script>
<!--[if lt IE 9]><script src="/w/resources/lib/html5shiv/html5shiv.js"></script><![endif]-->
</head>
<body class="mediawiki ltr sitedir-ltr mw-hide-empty-elt ns-0 ns-subject page-Glaucoma_Secondary_to_Intraocular_Tumors rootpage-Glaucoma_Secondary_to_Intraocular_Tumors layout-standard skin-chameleon action-view">
	<div class="flex-fill container">
		<div class="row">
			<div class="flex-grow-0 col-12 col-cmln-6 d-flex flex-column flex-md-row w-md-100 justify-content-start align-items-center col">
					<div class="float-left mr-3 mb-2"><a href="//aao.org"><img id="aao-logo" src="/w/extensions/EyeWiki/skins/chameleon/AAO_Logo.png"></a></div>
                		
				<!-- logo and main page link -->
				<div id="p-logo" class="p-logo" role="banner">
					<a href="/Main_Page" title="Visit the main page"><img src="/w/extensions/EyeWiki/skins/chameleon/EyeWiki_Logo.png" alt="EyeWiki"/></a>
				</div>
			</div>
			<div class="ml-auto col-12 col-cmln col">
				<div class="row">
					<div class="col">
						<!-- personal tools -->
						<div class="p-personal pull-right" id="p-personal" >
							<ul class="p-personal-tools" >
								<li id="pt-createaccount"><a href="/w/index.php?title=Special:CreateAccount&amp;returnto=Glaucoma+Secondary+to+Intraocular+Tumors" title="You are encouraged to create an account and log in; however, it is not mandatory" class="pt-createaccount">Create account</a></li>
								<li id="pt-login"><a href="/w/index.php?title=Special:UserLogin&amp;returnto=Glaucoma+Secondary+to+Intraocular+Tumors" title="You are encouraged to log in; however, it is not mandatory [o]" accesskey="o" class="pt-login">Log in</a></li>
							</ul>
						</div>

					</div>
				</div>
				<div class="row">
					<div class="col">
						<!-- search form -->
						<div  id="p-search" class="p-search pull-right" role="search"  >
							<form  id="searchform" class="mw-search" action="/w/index.php" >
								<input type="hidden" name="title" value=" Special:Search" />
								<div class="input-group">
									<input name="search" placeholder="Search EyeWiki" title="Search EyeWiki [f]" accesskey="f" id="searchInput" class="form-control"/>
									<div class="input-group-append">
										<button value="Go" id="searchGoButton" name="go" type="submit" class="search-btn searchGoButton" aria-label="Go to page" title="Go to a page with this exact name if it exists"></button>
									</div>
								</div>
							</form>
						</div>
					</div>
				</div>
			</div>
		</div>
		<div class="row">
			<div class="col">
				<!-- navigation bar -->
				<nav class="p-navbar collapsible mb-3 mt-2 p-1 mt-cmln-0" role="navigation" id="mw-navigation">
					<button type="button" class="navbar-toggler" data-toggle="collapse" data-target="#hbpzyvae91"></button>
					<div class="collapse navbar-collapse hbpzyvae91" id="hbpzyvae91">
						<div class="navbar-nav"><div class="nav-item"><a class="nav-link fas fa-home"  href="/Main_Page">Main Page</a></div><div class="nav-item"><a class="nav-link fas fa-book"  href="/Category:Articles">Articles</a></div><div class="nav-item"><a class="nav-link fas fa-play"  href="/Help:Getting_Started">Getting Started</a></div><div class="nav-item"><a class="nav-link fas fa-question"  href="/Help:Contents">Help</a></div><div class="nav-item"><a class="nav-link fas fa-backward"  href="/Special:RecentChanges">Recent changes</a></div><div class="nav-item"><a class="nav-link fas fa-door-open"  href="#">My Portal</a></div>
						</div>
					</div>
				</nav>
			</div>
		</div>
		<div class="row">
			<div class="col">
				<!-- Content navigation -->
				<div class="mb-3 pagetools p-contentnavigation" id="p-contentnavigation">
					<!-- namespaces -->
					<div id="p-namespaces" class="p-namespaces">
						<div class="tab-group">
							<div id="ca-nstab-main" class="selected"><a href="/Glaucoma_Secondary_to_Intraocular_Tumors" title="View the content page [c]" accesskey="c" class="selected ca-nstab-main">Page</a></div>
							<div id="ca-talk"><a href="/Talk:Glaucoma_Secondary_to_Intraocular_Tumors" rel="discussion" title="Discussion about the content page [t]" accesskey="t" class="ca-talk">Discussion</a></div>
						</div>
					</div>
					<!-- views -->
					<div id="p-views" class="p-views">
						<div class="tab-group">
							<div id="ca-formedit"><a href="/w/index.php?title=Glaucoma_Secondary_to_Intraocular_Tumors&amp;action=formedit" title="Edit this page with a form [&amp;]" accesskey="&amp;" class="ca-formedit">View form</a></div>
							<div id="ca-viewsource"><a href="/w/index.php?title=Glaucoma_Secondary_to_Intraocular_Tumors&amp;action=edit" title="This page is protected.&#10;You can view its source [e]" accesskey="e" class="ca-viewsource">View source</a></div>
							<div id="ca-history"><a href="/w/index.php?title=Glaucoma_Secondary_to_Intraocular_Tumors&amp;action=history" title="Past revisions of this page [h]" accesskey="h" class="ca-history">History</a></div>
						</div>
					</div>
				</div>
			</div>
		</div>
		<div class="row">
			<div class="col-auto mx-auto col">

			</div>
		</div>
		<div class="row">
			<div class="col-auto mx-auto col">
			</div>
		</div>
		<div class="row">
			<div class="col">
				<!-- start the content area -->
				<div id="content" class="mw-body content"><a id="top" class="top"></a>
					<div id="mw-indicators" class="mw-indicators">
					<div id="mw-indicator-smw-entity-examiner" class="mw-indicator mw-indicator-smw-entity-examiner"><div class="smw-entity-examiner smw-indicator-vertical-bar-loader" data-subject="Glaucoma_Secondary_to_Intraocular_Tumors#0##" data-dir="ltr" data-uselang="" title="Running an examiner in the background"></div></div>
				</div>
						<div class="contentHeader">
						<!-- title of the page -->
						<h1 id="firstHeading" class="firstHeading">Glaucoma Secondary to Intraocular Tumors</h1>
						<!-- tagline; usually goes something like "From WikiName" primary purpose of this seems to be for printing to identify the source of the content -->
						<div id="siteSub" class="siteSub">From EyeWiki</div><div id="jump-to-nav" class="mw-jump jump-to-nav">Jump to:<a href="#mw-navigation">navigation</a>, <a href="#p-search">search</a></div>
					</div>
					<div id="bodyContent" class="bodyContent">
						<!-- body text -->

						<div id="mw-content-text" lang="en" dir="ltr" class="mw-content-ltr"><div class="mw-parser-output"><div id="article-header" data-description2-ignore=""><div id="contest" style="margin-bottom: 6px;">
</div>
<div class="infobox contributors">
<div class="info-section" style="margin-bottom: 10px;">
<div class="info-section-header"><a href="/Property:Authors" title="Property:Authors">Article initiated by</a>:
</div>
<div class="info-section-body"><a href="/User:Ahmad.A.Aref" title="User:Ahmad.A.Aref">Ahmad A. Aref, MD, MBA</a>,&#8201;<a href="/w/index.php?title=User:Eric_G._Feinstein_MD&amp;action=formedit&amp;redlink=1" class="new" title="User:Eric G. Feinstein MD (page does not exist)">Eric G. Feinstein MD</a>
</div>
</div>
<div class="info-section" style="margin-bottom: 10px;">
<div class="info-section-header">All authors and contributors:
</div>
<div class="info-section-body"> <a href="/User:Brad.H.Feldman.DEC" title="User:Brad.H.Feldman.DEC">Brad H. Feldman, M.D.</a>,&#160;<a href="/User:Ahmad.A.Aref" title="User:Ahmad.A.Aref">Ahmad A. Aref, MD, MBA</a>,&#160;<a href="/User:Daniel.B.Moore" title="User:Daniel.B.Moore">Daniel B. Moore, MD</a>,&#160;<a href="/User:Qi.cui" title="User:Qi.cui">Qi N. Cui, MD PhD</a>
</div>
</div>
<div class="info-section" style="margin-bottom: 10px;">
<div class="info-section-header">Assigned editor:
</div>
<div class="info-section-body"> <a href="/User:Matthew.W.Wilson" title="User:Matthew.W.Wilson">Matthew W. Wilson, MD, FACS</a>,&#32;<a href="/User:Qi.cui" title="User:Qi.cui">Qi N. Cui, MD PhD</a></div>
</div><div class="info-section" style="margin-bottom: 10px;">
<div class="info-section-header">Review:
</div>
<div class="info-section-body">Assigned status <b>Up to Date</b>
</div>
</div>&#160;by <a href="/User:Qi.cui" title="User:Qi.cui">Qi N. Cui, MD PhD</a> on November 17, 2022.
</div>
<div style="display:none;">
<table cellspacing="5">

<tbody><tr>
<td><small><a rel="nofollow" class="external text" href="https://eyewiki.org/w/index.php?title=Glaucoma_Secondary_to_Intraocular_Tumors&amp;action=formedit">add</a></small>
</td></tr>
<tr>
<th align="right"><b><a href="/Property:Contributing_Editors" title="Property:Contributing Editors">Contributing Editors</a>:</b>
</th>
<td><small><a rel="nofollow" class="external text" href="https://eyewiki.org/w/index.php?title=Glaucoma_Secondary_to_Intraocular_Tumors&amp;action=formedit">add</a></small>
</td></tr>
</tbody></table> </div>
<div style="display:none;">
<p><br />
</p>
</div>
<div id="local-videos">
</div>
</div>
<p>Ocular tumors or systemic malignancies that spread to the eye can lead to intraocular pressure elevation through many different mechanisms. If not diagnosed early, the tumor’s effect on eye pressure or spread of the tumor itself can be sight or life threatening. In patients with highly asymmetric glaucoma or eye pressure elevation that is resistant to standard medical therapy, a thorough history and ocular exam (including pertinent imaging) should be performed to rule out intraocular malignancies. 
</p><p><br />
</p>
<div id="toc" class="toc" role="navigation" aria-labelledby="mw-toc-heading"><input type="checkbox" role="button" id="toctogglecheckbox" class="toctogglecheckbox" style="display:none" /><div class="toctitle" lang="en" dir="ltr"><h2 id="mw-toc-heading">Contents</h2><span class="toctogglespan"><label class="toctogglelabel" for="toctogglecheckbox"></label></span></div>
<ul>
<li class="toclevel-1 tocsection-1"><a href="#Disease"><span class="tocnumber">1</span> <span class="toctext">Disease</span></a></li>
<li class="toclevel-1 tocsection-2"><a href="#Etiology"><span class="tocnumber">2</span> <span class="toctext">Etiology</span></a></li>
<li class="toclevel-1 tocsection-3"><a href="#Pathophysiology"><span class="tocnumber">3</span> <span class="toctext">Pathophysiology</span></a>
<ul>
<li class="toclevel-2 tocsection-4"><a href="#Open_Angle_Glaucoma"><span class="tocnumber">3.1</span> <span class="toctext">Open Angle Glaucoma</span></a>
<ul>
<li class="toclevel-3 tocsection-5"><a href="#Direct_Invasion_of_Anterior_Chamber_Angle"><span class="tocnumber">3.1.1</span> <span class="toctext">Direct Invasion of Anterior Chamber Angle</span></a></li>
<li class="toclevel-3 tocsection-6"><a href="#Secondary_Pigmentary_Glaucoma"><span class="tocnumber">3.1.2</span> <span class="toctext">Secondary Pigmentary Glaucoma</span></a></li>
<li class="toclevel-3 tocsection-7"><a href="#Melanomalytic_Glaucoma"><span class="tocnumber">3.1.3</span> <span class="toctext">Melanomalytic Glaucoma</span></a></li>
<li class="toclevel-3 tocsection-8"><a href="#Anterior_Chamber_Angle_Epithelialization"><span class="tocnumber">3.1.4</span> <span class="toctext">Anterior Chamber Angle Epithelialization</span></a></li>
<li class="toclevel-3 tocsection-9"><a href="#Increased_Episcleral_Venous_Pressure"><span class="tocnumber">3.1.5</span> <span class="toctext">Increased Episcleral Venous Pressure</span></a></li>
</ul>
</li>
<li class="toclevel-2 tocsection-10"><a href="#Closed_Angle_Glaucoma"><span class="tocnumber">3.2</span> <span class="toctext">Closed Angle Glaucoma</span></a>
<ul>
<li class="toclevel-3 tocsection-11"><a href="#Uveitic"><span class="tocnumber">3.2.1</span> <span class="toctext">Uveitic</span></a></li>
<li class="toclevel-3 tocsection-12"><a href="#Secondary_Neovascularization"><span class="tocnumber">3.2.2</span> <span class="toctext">Secondary Neovascularization</span></a></li>
<li class="toclevel-3 tocsection-13"><a href="#Anterior_Displacement_of_Lens-Iris_Diaphragm"><span class="tocnumber">3.2.3</span> <span class="toctext">Anterior Displacement of Lens-Iris Diaphragm</span></a></li>
</ul>
</li>
</ul>
</li>
<li class="toclevel-1 tocsection-14"><a href="#Diagnosis"><span class="tocnumber">4</span> <span class="toctext">Diagnosis</span></a>
<ul>
<li class="toclevel-2 tocsection-15"><a href="#History"><span class="tocnumber">4.1</span> <span class="toctext">History</span></a></li>
<li class="toclevel-2 tocsection-16"><a href="#Symptoms"><span class="tocnumber">4.2</span> <span class="toctext">Symptoms</span></a></li>
<li class="toclevel-2 tocsection-17"><a href="#Physical_examination"><span class="tocnumber">4.3</span> <span class="toctext">Physical examination</span></a>
<ul>
<li class="toclevel-3 tocsection-18"><a href="#Anterior_Segment_Exam_Findings"><span class="tocnumber">4.3.1</span> <span class="toctext">Anterior Segment Exam Findings</span></a></li>
<li class="toclevel-3 tocsection-19"><a href="#Posterior_segment_Findings:"><span class="tocnumber">4.3.2</span> <span class="toctext">Posterior segment Findings:</span></a></li>
</ul>
</li>
<li class="toclevel-2 tocsection-20"><a href="#Ophthalmic_Imaging"><span class="tocnumber">4.4</span> <span class="toctext">Ophthalmic Imaging</span></a>
<ul>
<li class="toclevel-3 tocsection-21"><a href="#B-Scan_Ultrasonography_.28B-Scan.29"><span class="tocnumber">4.4.1</span> <span class="toctext"><b>B-Scan Ultrasonography (B-Scan)</b></span></a></li>
<li class="toclevel-3 tocsection-22"><a href="#Ultrasound_Biomicroscopy_.28UBM.29"><span class="tocnumber">4.4.2</span> <span class="toctext"><b>Ultrasound Biomicroscopy (UBM)</b></span></a></li>
</ul>
</li>
<li class="toclevel-2 tocsection-23"><a href="#Diagnostic_procedures"><span class="tocnumber">4.5</span> <span class="toctext">Diagnostic procedures</span></a></li>
<li class="toclevel-2 tocsection-24"><a href="#Differential_diagnosis"><span class="tocnumber">4.6</span> <span class="toctext">Differential diagnosis</span></a>
<ul>
<li class="toclevel-3 tocsection-25"><a href="#Leukemia"><span class="tocnumber">4.6.1</span> <span class="toctext"><b>Leukemia</b></span></a></li>
<li class="toclevel-3 tocsection-26"><a href="#Lymphoma"><span class="tocnumber">4.6.2</span> <span class="toctext"><b>Lymphoma</b></span></a></li>
<li class="toclevel-3 tocsection-27"><a href="#Metastatic_Tumors"><span class="tocnumber">4.6.3</span> <span class="toctext"><b>Metastatic Tumors</b></span></a></li>
<li class="toclevel-3 tocsection-28"><a href="#Uveal_Melanoma"><span class="tocnumber">4.6.4</span> <span class="toctext"><b>Uveal Melanoma</b></span></a></li>
<li class="toclevel-3 tocsection-29"><a href="#Retinoblastoma"><span class="tocnumber">4.6.5</span> <span class="toctext"><b>Retinoblastoma</b></span></a></li>
<li class="toclevel-3 tocsection-30"><a href="#Other_Tumors"><span class="tocnumber">4.6.6</span> <span class="toctext"><b>Other Tumors</b></span></a></li>
</ul>
</li>
</ul>
</li>
<li class="toclevel-1 tocsection-31"><a href="#Management"><span class="tocnumber">5</span> <span class="toctext">Management</span></a>
<ul>
<li class="toclevel-2 tocsection-32"><a href="#Medical_therapy"><span class="tocnumber">5.1</span> <span class="toctext">Medical therapy</span></a></li>
<li class="toclevel-2 tocsection-33"><a href="#Surgery"><span class="tocnumber">5.2</span> <span class="toctext">Surgery</span></a></li>
<li class="toclevel-2 tocsection-34"><a href="#Complications"><span class="tocnumber">5.3</span> <span class="toctext">Complications</span></a></li>
<li class="toclevel-2 tocsection-35"><a href="#Prognosis"><span class="tocnumber">5.4</span> <span class="toctext">Prognosis</span></a></li>
</ul>
</li>
<li class="toclevel-1 tocsection-36"><a href="#References"><span class="tocnumber">6</span> <span class="toctext">References</span></a></li>
</ul>
</div>

<h1><span class="mw-headline" id="Disease">Disease</span></h1>
<p>Tumors within the globe can lead to elevation in intraocular pressure (IOP) and permanent damage to the ocular structures. In patients who present with atypical, unilateral or highly asymmetric glaucoma, suspicion for intraocular malignancies must be high.<sup id="cite_ref-radcliffe1_1-0" class="reference"><a href="#cite_note-radcliffe1-1">&#91;1&#93;</a></sup> <sup id="cite_ref-shields2_2-0" class="reference"><a href="#cite_note-shields2-2">&#91;2&#93;</a></sup> The type of tumor, the location of the malignancy and the size of the mass affects the amount of pressure elevation within the globe. The pressure can be further increased depending on the amount of inflammation, necrosis, or hemorrhage present.<sup id="cite_ref-radcliffe1_1-1" class="reference"><a href="#cite_note-radcliffe1-1">&#91;1&#93;</a></sup><sup id="cite_ref-ferry3_3-0" class="reference"><a href="#cite_note-ferry3-3">&#91;3&#93;</a></sup> <sup id="cite_ref-ferry4_4-0" class="reference"><a href="#cite_note-ferry4-4">&#91;4&#93;</a></sup> <sup id="cite_ref-bollinger5_5-0" class="reference"><a href="#cite_note-bollinger5-5">&#91;5&#93;</a></sup> The prevalence of ocular metastasis from systemic tumors is estimated to be around 4%.<sup id="cite_ref-nelson6_6-0" class="reference"><a href="#cite_note-nelson6-6">&#91;6&#93;</a></sup>
</p>
<h1><span class="mw-headline" id="Etiology">Etiology</span></h1>
<p>The majority of tumors that are found within ocular tissues are generally from distant sources that spread to the eye through the vascular/lymphatic system or rarely by direct invasion from surrounding tissues. Most systemic tumors affect the choroid with breast, lung and kidney being the most common primary sites.<sup id="cite_ref-shields7_7-0" class="reference"><a href="#cite_note-shields7-7">&#91;7&#93;</a></sup> 
</p><p>Overall, in eyes which have intraocular tumors the prevalence of elevation in IOP is around 5%.<sup id="cite_ref-shields8_8-0" class="reference"><a href="#cite_note-shields8-8">&#91;8&#93;</a></sup> The type as well as location of the intraocular malignancy affect the likelihood of causing elevations in IOP.<sup id="cite_ref-ferry3_3-1" class="reference"><a href="#cite_note-ferry3-3">&#91;3&#93;</a></sup><sup id="cite_ref-ferry4_4-1" class="reference"><a href="#cite_note-ferry4-4">&#91;4&#93;</a></sup> For patients with metastasis or uveal melanoma, an increase in IOP is much more common in tumors affecting the anterior uveal tract including the ciliary body and the iris.<sup id="cite_ref-shields8_8-1" class="reference"><a href="#cite_note-shields8-8">&#91;8&#93;</a></sup> <sup id="cite_ref-shields9_9-0" class="reference"><a href="#cite_note-shields9-9">&#91;9&#93;</a></sup>  For iris metastasis or melanoma the rate of secondary glaucoma can be as high as one-third.<sup id="cite_ref-shields10_10-0" class="reference"><a href="#cite_note-shields10-10">&#91;10&#93;</a></sup> <sup id="cite_ref-shields11_11-0" class="reference"><a href="#cite_note-shields11-11">&#91;11&#93;</a></sup>
</p>
<h1><span class="mw-headline" id="Pathophysiology">Pathophysiology</span></h1>
<h2><span class="mw-headline" id="Open_Angle_Glaucoma">Open Angle Glaucoma</span></h2>
<h3><span class="mw-headline" id="Direct_Invasion_of_Anterior_Chamber_Angle">Direct Invasion of Anterior Chamber Angle</span></h3>
<p>In tumors located in the anterior segment of the eye, the most common mechanism for secondary IOP elevation is direct invasion of the anterior chamber angle by tumor cells. This mechanically prevents aqueous humor from egressing the eye, which directly causes a rise in IOP. This can been seen clinically on gonioscopy as well as at the ultrastructural level using immunohistochemistry and electron microscopy of affected ocular tissues.<sup id="cite_ref-krohn17_12-0" class="reference"><a href="#cite_note-krohn17-12">&#91;12&#93;</a></sup> 
</p><p>For all anteriorly located metastatic tumors and iris melanomas, mechanical obstruction is the most common cause of secondary glaucoma.<sup id="cite_ref-shields2_2-1" class="reference"><a href="#cite_note-shields2-2">&#91;2&#93;</a></sup> Ring melanoma, which involves most of the ciliary body and iris, blocks aqueous outflow as it spreads circumferentially.<sup id="cite_ref-shields9_9-1" class="reference"><a href="#cite_note-shields9-9">&#91;9&#93;</a></sup><sup id="cite_ref-shields10_10-1" class="reference"><a href="#cite_note-shields10-10">&#91;10&#93;</a></sup><sup id="cite_ref-Demirci13_13-0" class="reference"><a href="#cite_note-Demirci13-13">&#91;13&#93;</a></sup> Not every patient with seeding of the angle will develop glaucoma. Tumors with the following characteristics are more likely to develop elevated IOP: larger tumor base, iris root location of tumor base, flat contour of tumors and tumors with a large number of clock hours of angl<b>e</b> seeding.<sup id="cite_ref-shields8_8-2" class="reference"><a href="#cite_note-shields8-8">&#91;8&#93;</a></sup><sup id="cite_ref-shields11_11-1" class="reference"><a href="#cite_note-shields11-11">&#91;11&#93;</a></sup><sup id="cite_ref-mcmenamin12_14-0" class="reference"><a href="#cite_note-mcmenamin12-14">&#91;14&#93;</a></sup><sup id="cite_ref-lee14_15-0" class="reference"><a href="#cite_note-lee14-15">&#91;15&#93;</a></sup>
</p>
<h3><span class="mw-headline" id="Secondary_Pigmentary_Glaucoma">Secondary Pigmentary Glaucoma</span></h3>
<p>Massive dispersion of pigment from pigmented tumor cells (i.e.- melanoma and melanocytoma) can lead to obstruction of the anterior chamber angle and iris heterochromia.<sup id="cite_ref-shields7_7-1" class="reference"><a href="#cite_note-shields7-7">&#91;7&#93;</a></sup><sup id="cite_ref-krohn17_12-1" class="reference"><a href="#cite_note-krohn17-12">&#91;12&#93;</a></sup><sup id="cite_ref-de18_16-0" class="reference"><a href="#cite_note-de18-16">&#91;16&#93;</a></sup><sup id="cite_ref-fabreguillevin53_17-0" class="reference"><a href="#cite_note-fabreguillevin53-17">&#91;17&#93;</a></sup> In ciliary body melanomas this is the most common cause of secondary glaucoma.<sup id="cite_ref-shields2_2-2" class="reference"><a href="#cite_note-shields2-2">&#91;2&#93;</a></sup> 
</p>
<h3><span class="mw-headline" id="Melanomalytic_Glaucoma">Melanomalytic Glaucoma</span></h3>
<p>Melanomalytic glaucoma is secondary to the release of pigment from tumor cells which are subsequently phagocytosed by macrophages.<sup id="cite_ref-yanoff15_18-0" class="reference"><a href="#cite_note-yanoff15-18">&#91;18&#93;</a></sup> <sup id="cite_ref-fineman16_19-0" class="reference"><a href="#cite_note-fineman16-19">&#91;19&#93;</a></sup> Based on studies using immunohistochemistry and electron microscopy, these pigment-laden macrophages cause blockage of the trabecular meshwork which leads to increased IOP.<sup id="cite_ref-shields7_7-2" class="reference"><a href="#cite_note-shields7-7">&#91;7&#93;</a></sup><sup id="cite_ref-yanoff15_18-1" class="reference"><a href="#cite_note-yanoff15-18">&#91;18&#93;</a></sup><sup id="cite_ref-fineman16_19-1" class="reference"><a href="#cite_note-fineman16-19">&#91;19&#93;</a></sup><sup id="cite_ref-krohn17_12-2" class="reference"><a href="#cite_note-krohn17-12">&#91;12&#93;</a></sup> 
</p>
<h3><span class="mw-headline" id="Anterior_Chamber_Angle_Epithelialization">Anterior Chamber Angle Epithelialization</span></h3>
<p>A sheet-like plaque of malignant tumor cells that spread over an open anterior chamber angle can cause mechanical obstruction of the trabecular meshwork. This causes IOP elevation and secondary open-angle glaucoma.<sup id="cite_ref-mcmenamin12_14-1" class="reference"><a href="#cite_note-mcmenamin12-14">&#91;14&#93;</a></sup> 
</p>
<h3><span class="mw-headline" id="Increased_Episcleral_Venous_Pressure">Increased Episcleral Venous Pressure</span></h3>
<p>Aqueous humor outflow is dependent on the pressure gradient between IOP and episcleral venous pressure. Orbital tumors or extraocular extension of an intraocular tumor can cause an increase in episcleral venous pressure through direct compression. <sup id="cite_ref-matano35_20-0" class="reference"><a href="#cite_note-matano35-20">&#91;20&#93;</a></sup> Resulting elevation of episcleral venous pressure causes a pressure gradient reduction, contributing to secondary glaucoma.<sup id="cite_ref-j.C3.B8rgensen19_21-0" class="reference"><a href="#cite_note-j.C3.B8rgensen19-21">&#91;21&#93;</a></sup>
</p>
<h2><span class="mw-headline" id="Closed_Angle_Glaucoma">Closed Angle Glaucoma</span></h2>
<h3><span class="mw-headline" id="Uveitic">Uveitic</span></h3>
<p>Inflammation secondary to intraocular tumors can cause obstruction of the outflow pathway by inflammatory cells as well as peripheral anterior synechiae, which can lead to secondary angle closure. In patients with uveal melanoma and uveitis, secondary angle closure is common from peripheral anterior synechiae.<sup id="cite_ref-shields7_7-3" class="reference"><a href="#cite_note-shields7-7">&#91;7&#93;</a></sup> Metastatic tumors have also been shown to cause significant inflammation leading to outflow obstruction and synechial angle closure.<sup id="cite_ref-girkin47_22-0" class="reference"><a href="#cite_note-girkin47-22">&#91;22&#93;</a></sup>
</p>
<h3><span class="mw-headline" id="Secondary_Neovascularization">Secondary Neovascularization</span></h3>
<p>Patients with intraocular tumors can often develop neovascularization of the iris and angle, which can lead to chronic angle closure glaucoma. This is commonly true in tumors which cause a chronic retinal detachment (especially choroidal melanomas) leading to ischemia and resultant secondary neovascularization.<sup id="cite_ref-radcliffe1_1-2" class="reference"><a href="#cite_note-radcliffe1-1">&#91;1&#93;</a></sup><sup id="cite_ref-girkin47_22-1" class="reference"><a href="#cite_note-girkin47-22">&#91;22&#93;</a></sup> Metastatic cutaneous melanomas are also highly associated with neovascularization.<sup id="cite_ref-garrison20_23-0" class="reference"><a href="#cite_note-garrison20-23">&#91;23&#93;</a></sup> Neovascularization can also be present as a complication of tumor treatment (i.e., after radiation).<sup id="cite_ref-bollinger5_5-1" class="reference"><a href="#cite_note-bollinger5-5">&#91;5&#93;</a></sup><sup id="cite_ref-bergmann29_24-0" class="reference"><a href="#cite_note-bergmann29-24">&#91;24&#93;</a></sup><sup id="cite_ref-chang44_25-0" class="reference"><a href="#cite_note-chang44-25">&#91;25&#93;</a></sup><sup id="cite_ref-albert46_26-0" class="reference"><a href="#cite_note-albert46-26">&#91;26&#93;</a></sup><sup id="cite_ref-naumann48_27-0" class="reference"><a href="#cite_note-naumann48-27">&#91;27&#93;</a></sup> 
</p>
<h3><span class="mw-headline" id="Anterior_Displacement_of_Lens-Iris_Diaphragm">Anterior Displacement of Lens-Iris Diaphragm</span></h3>
<p>The most common mechanism of angle closure in patients with intraocular tumor is forward displacement of the lens-iris diaphragm. The displacement is usually from a large mass in the posterior segment of the eye causing forward pressure on iris and lens structures leading to pupillary block, iris bombé, and/or peripheral anterior synechiae closing the anterior chamber angle.<sup id="cite_ref-shields7_7-4" class="reference"><a href="#cite_note-shields7-7">&#91;7&#93;</a></sup><sup id="cite_ref-girkin47_22-2" class="reference"><a href="#cite_note-girkin47-22">&#91;22&#93;</a></sup><sup id="cite_ref-gunduz22_28-0" class="reference"><a href="#cite_note-gunduz22-28">&#91;28&#93;</a></sup>
</p>
<h1><span class="mw-headline" id="Diagnosis">Diagnosis</span></h1>
<h2><span class="mw-headline" id="History">History</span></h2>
<p>The workup begins with a thorough history, which should be performed in all patients with elevated IOP from atypical cases of glaucoma. A thorough history includes all of the following: 
</p>
<ul><li>Complete history of present illness (including current and past symptoms)</li>
<li>Past medical and ocular history (focusing specifically on risk factors for cancer)</li>
<li>Past surgical history (including radiation treatments)</li>
<li>Medications (including eye drops)</li>
<li>Family history (especially cancer history)</li>
<li>Complete review of systems</li>
<li>Social history (including drugs, tobacco use, alcohol and occupation)</li></ul>
<h2><span class="mw-headline" id="Symptoms">Symptoms</span></h2>
<p>The symptoms that the patient experience depend greatly on the type and location of the malignancy as well as the amount of ocular involvement. The most frequently recorded symptoms are blurred vision, pain, redness and floaters. <sup id="cite_ref-shields8_8-3" class="reference"><a href="#cite_note-shields8-8">&#91;8&#93;</a></sup><sup id="cite_ref-shields11_11-2" class="reference"><a href="#cite_note-shields11-11">&#91;11&#93;</a></sup><sup id="cite_ref-mcmenamin12_14-2" class="reference"><a href="#cite_note-mcmenamin12-14">&#91;14&#93;</a></sup><sup id="cite_ref-puusaari25_29-0" class="reference"><a href="#cite_note-puusaari25-29">&#91;29&#93;</a></sup> Some patients, however, are asymptomatic. 
</p>
<h2><span class="mw-headline" id="Physical_examination">Physical examination</span></h2>
<p>Extraocular and slit lamp biomicroscopy exams of the anterior and posterior segments of each eye should be performed as well as a thorough gonioscopy of the angle. A complete dilated exam should be performed in all patients, as long as the anterior chamber angle is not occludable. The following findings are essential to note for any patient suspected of having tumor induced secondary glaucoma. <sup id="cite_ref-radcliffe1_1-3" class="reference"><a href="#cite_note-radcliffe1-1">&#91;1&#93;</a></sup><sup id="cite_ref-shields7_7-5" class="reference"><a href="#cite_note-shields7-7">&#91;7&#93;</a></sup><sup id="cite_ref-shields8_8-4" class="reference"><a href="#cite_note-shields8-8">&#91;8&#93;</a></sup><sup id="cite_ref-shields9_9-2" class="reference"><a href="#cite_note-shields9-9">&#91;9&#93;</a></sup><sup id="cite_ref-shields11_11-3" class="reference"><a href="#cite_note-shields11-11">&#91;11&#93;</a></sup><sup id="cite_ref-mcmenamin12_14-3" class="reference"><a href="#cite_note-mcmenamin12-14">&#91;14&#93;</a></sup><sup id="cite_ref-fabreguillevin53_17-1" class="reference"><a href="#cite_note-fabreguillevin53-17">&#91;17&#93;</a></sup><sup id="cite_ref-yanoff15_18-2" class="reference"><a href="#cite_note-yanoff15-18">&#91;18&#93;</a></sup><sup id="cite_ref-schuman34_30-0" class="reference"><a href="#cite_note-schuman34-30">&#91;30&#93;</a></sup>  
</p>
<h3><span class="mw-headline" id="Anterior_Segment_Exam_Findings">Anterior Segment Exam Findings</span></h3>
<ul><li>Pigment dispersion (in anterior chamber or angle)</li>
<li>Dilated episcleral vessels</li>
<li>Intraocular inflammation (noting cell/flare, hypopyon, or keratic precipitates)</li>
<li>Hyphema</li>
<li>Heterochromia</li>
<li>Neovascularization of Iris or Angle</li>
<li>Mass lesions of the iris/ciliary body/angle</li>
<li>Abnormal transillumination of the globe (noting shadows suggestive of a masses)</li>
<li>Closed/narrow angle</li></ul>
<h3><span class="mw-headline" id="Posterior_segment_Findings:">Posterior segment Findings:</span></h3>
<ul><li>Retinal detachment</li>
<li>Posterior segment masses</li>
<li>Vitritis</li>
<li>Vitreous hemorrhage</li></ul>
<h2><span class="mw-headline" id="Ophthalmic_Imaging">Ophthalmic Imaging</span></h2>
<h4><span id="B-Scan_Ultrasonography_(B-Scan)"></span><span class="mw-headline" id="B-Scan_Ultrasonography_.28B-Scan.29"><b>B-Scan Ultrasonography (B-Scan)</b></span></h4>
<p>In patients in whom dilation is not possible (patients at risk for angle closure) or if there is opacification of the media obstructing the view to the posterior pole, B-scan ultrasound can be used to examine the posterior segment. Specifically, it is helpful in taking measurements of the posterior segment tumors like uveal melanomas and looking for concurrent retinal detachments, vitreous hemorrhage or vitritis. 
</p>
<h4><span id="Ultrasound_Biomicroscopy_(UBM)"></span><span class="mw-headline" id="Ultrasound_Biomicroscopy_.28UBM.29"><b>Ultrasound Biomicroscopy (UBM)</b></span></h4>
<p>To further characterize tumors in the anterior segment including the ciliary body, ultrasound biomicroscopy can be performed. UBM uses a high frequency wavelength which allows for accurate measurements of lesion size and is helpful for diagnosis (solid versus cystic masses) and follow up.<sup id="cite_ref-radcliffe1_1-4" class="reference"><a href="#cite_note-radcliffe1-1">&#91;1&#93;</a></sup><sup id="cite_ref-gunduz22_28-1" class="reference"><a href="#cite_note-gunduz22-28">&#91;28&#93;</a></sup><sup id="cite_ref-van36_31-0" class="reference"><a href="#cite_note-van36-31">&#91;31&#93;</a></sup> 
</p>
<h2><span class="mw-headline" id="Diagnostic_procedures">Diagnostic procedures</span></h2>
<p>If diagnostic uncertainty remains after a full history, physical exam, and imaging, a diagnostic biopsy can be performed for most tumors (it is contraindicated in retinoblastoma). The use of fine needle aspiration biopsy with either a 25-gauge needle or a vitrector can be performed, and the sample analyzed with or without immunohistochemistry to help with diagnosis. This method has proven to be especially helpful in leukemia/lymphoma.<sup id="cite_ref-ellsworth23_32-0" class="reference"><a href="#cite_note-ellsworth23-32">&#91;32&#93;</a></sup> <sup id="cite_ref-conway24_33-0" class="reference"><a href="#cite_note-conway24-33">&#91;33&#93;</a></sup><sup id="cite_ref-sullivan37_34-0" class="reference"><a href="#cite_note-sullivan37-34">&#91;34&#93;</a></sup> <sup id="cite_ref-feinstein38_35-0" class="reference"><a href="#cite_note-feinstein38-35">&#91;35&#93;</a></sup> 
</p>
<h2><span class="mw-headline" id="Differential_diagnosis">Differential diagnosis</span></h2>
<h4><span class="mw-headline" id="Leukemia"><b>Leukemia</b></span></h4>
<p>Involvement of the eye can occur in just under one-third of cases of systemic leukemia.<sup id="cite_ref-nelson6_6-1" class="reference"><a href="#cite_note-nelson6-6">&#91;6&#93;</a></sup> Secondary glaucoma is generally caused by anterior chamber angle obstruction from leukemic cells.<sup id="cite_ref-schuman34_30-1" class="reference"><a href="#cite_note-schuman34-30">&#91;30&#93;</a></sup> Acute lymphoblastic (ALL) and acute myelogenous (AML) leukemias are the most common causes of secondary glaucoma in patients with leukemia.<sup id="cite_ref-radcliffe1_1-5" class="reference"><a href="#cite_note-radcliffe1-1">&#91;1&#93;</a></sup><sup id="cite_ref-nelson6_6-2" class="reference"><a href="#cite_note-nelson6-6">&#91;6&#93;</a></sup> On examination, due to layering of the leukemic cells, there may be a pseudohypopyon present in the anterior chamber.<sup id="cite_ref-matano35_20-1" class="reference"><a href="#cite_note-matano35-20">&#91;20&#93;</a></sup> Secondary angle closure glaucoma has also been reported.<sup id="cite_ref-shields8_8-5" class="reference"><a href="#cite_note-shields8-8">&#91;8&#93;</a></sup>
</p>
<h4><span class="mw-headline" id="Lymphoma"><b>Lymphoma</b></span></h4>
<p>Non-Hodgkin lymphoma of the central nervous system (NHL-CNS) tend to more commonly affect the eye compared to non-CNS involving lymphoma.<sup id="cite_ref-radcliffe1_1-6" class="reference"><a href="#cite_note-radcliffe1-1">&#91;1&#93;</a></sup><sup id="cite_ref-nelson6_6-3" class="reference"><a href="#cite_note-nelson6-6">&#91;6&#93;</a></sup><sup id="cite_ref-shields8_8-6" class="reference"><a href="#cite_note-shields8-8">&#91;8&#93;</a></sup><sup id="cite_ref-velez33_36-0" class="reference"><a href="#cite_note-velez33-36">&#91;36&#93;</a></sup> NHL-CNS classically affects the retina and vitreous with patients complaining of floaters.<sup id="cite_ref-velez33_36-1" class="reference"><a href="#cite_note-velez33-36">&#91;36&#93;</a></sup><sup id="cite_ref-mashayekhi32_37-0" class="reference"><a href="#cite_note-mashayekhi32-37">&#91;37&#93;</a></sup><sup id="cite_ref-cooper27_38-0" class="reference"><a href="#cite_note-cooper27-38">&#91;38&#93;</a></sup> On anterior segment examination, there can be signs of inflammation (cell/flare, keratic precipitates), hyphema, corneal edema and/or a pseudohypopyon (layered tumor cells). On posterior segment exam, vitritis and subretinal infiltrates may be present.<sup id="cite_ref-matano35_20-2" class="reference"><a href="#cite_note-matano35-20">&#91;20&#93;</a></sup> <sup id="cite_ref-cooper27_38-1" class="reference"><a href="#cite_note-cooper27-38">&#91;38&#93;</a></sup><sup id="cite_ref-mashayekhi32_37-1" class="reference"><a href="#cite_note-mashayekhi32-37">&#91;37&#93;</a></sup> Non-CNS intraocular lymphoma often metastasize through the choroidal circulation to the uveal tissue. Symptoms usually include pain, blurred vision and eye redness.<sup id="cite_ref-velez33_36-2" class="reference"><a href="#cite_note-velez33-36">&#91;36&#93;</a></sup><sup id="cite_ref-cooper27_38-2" class="reference"><a href="#cite_note-cooper27-38">&#91;38&#93;</a></sup><sup id="cite_ref-mashayekhi32_37-2" class="reference"><a href="#cite_note-mashayekhi32-37">&#91;37&#93;</a></sup> 
</p><p>Lymphoma with metastasis to the eye tends to occur at a lower rate compared to leukemia. Secondary elevation of IOP more commonly occurs from tumor seeding of the trabecular meshwork, but angle closure and iris neovascularization have also been reported. <sup id="cite_ref-shields8_8-7" class="reference"><a href="#cite_note-shields8-8">&#91;8&#93;</a></sup><sup id="cite_ref-matano35_20-3" class="reference"><a href="#cite_note-matano35-20">&#91;20&#93;</a></sup><sup id="cite_ref-van36_31-1" class="reference"><a href="#cite_note-van36-31">&#91;31&#93;</a></sup><sup id="cite_ref-sullivan37_34-1" class="reference"><a href="#cite_note-sullivan37-34">&#91;34&#93;</a></sup><sup id="cite_ref-mashayekhi32_37-3" class="reference"><a href="#cite_note-mashayekhi32-37">&#91;37&#93;</a></sup>
</p>
<h4><span class="mw-headline" id="Metastatic_Tumors"><b>Metastatic Tumors</b></span></h4>
<p>The most common type of intraocular tumor results from metastases. These tumors are most frequently located in the uveal tract, with the most common primary sites being breast and lung.<sup id="cite_ref-ferry3_3-2" class="reference"><a href="#cite_note-ferry3-3">&#91;3&#93;</a></sup><sup id="cite_ref-ferry4_4-2" class="reference"><a href="#cite_note-ferry4-4">&#91;4&#93;</a></sup><sup id="cite_ref-shields7_7-6" class="reference"><a href="#cite_note-shields7-7">&#91;7&#93;</a></sup><sup id="cite_ref-shields10_10-2" class="reference"><a href="#cite_note-shields10-10">&#91;10&#93;</a></sup><sup id="cite_ref-chin21_39-0" class="reference"><a href="#cite_note-chin21-39">&#91;39&#93;</a></sup> Besides leukemia and lymphoma, carcinomas are more common than sarcomas in terms of metastasis to the eye.<sup id="cite_ref-nelson6_6-4" class="reference"><a href="#cite_note-nelson6-6">&#91;6&#93;</a></sup><sup id="cite_ref-feinstein38_35-1" class="reference"><a href="#cite_note-feinstein38-35">&#91;35&#93;</a></sup> These patients have symptoms of decreased vision and pain and may have exophthalmos, retinal detachment, mass lesions, uveitis, and secondary glaucoma on exam.<sup id="cite_ref-ferry3_3-3" class="reference"><a href="#cite_note-ferry3-3">&#91;3&#93;</a></sup> 
</p><p>Secondary IOP elevations is much more common in anteriorly located metastatic tumors.<sup id="cite_ref-ferry3_3-4" class="reference"><a href="#cite_note-ferry3-3">&#91;3&#93;</a></sup><sup id="cite_ref-ferry4_4-3" class="reference"><a href="#cite_note-ferry4-4">&#91;4&#93;</a></sup> The mechanism of IOP elevation is generally from direct invasion of the anterior chamber angle but neovascularization has also been reported.<sup id="cite_ref-ferry3_3-5" class="reference"><a href="#cite_note-ferry3-3">&#91;3&#93;</a></sup><sup id="cite_ref-ferry4_4-4" class="reference"><a href="#cite_note-ferry4-4">&#91;4&#93;</a></sup><sup id="cite_ref-shields9_9-3" class="reference"><a href="#cite_note-shields9-9">&#91;9&#93;</a></sup> In one histopathological study of patients with metastatic carcinomas to the eye, high IOP was present in 7.5%.<sup id="cite_ref-ferry3_3-6" class="reference"><a href="#cite_note-ferry3-3">&#91;3&#93;</a></sup> Due to the general health and infrequent ophthalmic exams received by these patients, many metastatic tumors and secondary glaucomas may go undetected.
</p>
<h4><span class="mw-headline" id="Uveal_Melanoma"><b>Uveal Melanoma</b></span></h4>
<p>The most common primary intraocular malignancy in adults is uveal melanoma with the majority located within the choroid.<sup id="cite_ref-radcliffe1_1-7" class="reference"><a href="#cite_note-radcliffe1-1">&#91;1&#93;</a></sup><sup id="cite_ref-shields2_2-3" class="reference"><a href="#cite_note-shields2-2">&#91;2&#93;</a></sup><sup id="cite_ref-shields8_8-8" class="reference"><a href="#cite_note-shields8-8">&#91;8&#93;</a></sup><sup id="cite_ref-wanner28_40-0" class="reference"><a href="#cite_note-wanner28-40">&#91;40&#93;</a></sup><sup id="cite_ref-faulknerjones30_41-0" class="reference"><a href="#cite_note-faulknerjones30-41">&#91;41&#93;</a></sup> Elevation of IOP has been reported in up to one-fourth of patients with uveal melanoma through a variety of mechanisms causing both open and closed angle glaucomas.<sup id="cite_ref-shields2_2-4" class="reference"><a href="#cite_note-shields2-2">&#91;2&#93;</a></sup><sup id="cite_ref-shields8_8-9" class="reference"><a href="#cite_note-shields8-8">&#91;8&#93;</a></sup> 
</p><p>Open angle glaucoma in uveal melanoma patients can occur due to tumor seeding of the anterior chamber angle, direct invasion of the tumor into the angle and melanomalytic obstruction.<sup id="cite_ref-shields2_2-5" class="reference"><a href="#cite_note-shields2-2">&#91;2&#93;</a></sup><sup id="cite_ref-shields8_8-10" class="reference"><a href="#cite_note-shields8-8">&#91;8&#93;</a></sup><sup id="cite_ref-krohn17_12-3" class="reference"><a href="#cite_note-krohn17-12">&#91;12&#93;</a></sup><sup id="cite_ref-mcmenamin12_14-4" class="reference"><a href="#cite_note-mcmenamin12-14">&#91;14&#93;</a></sup><sup id="cite_ref-yanoff15_18-3" class="reference"><a href="#cite_note-yanoff15-18">&#91;18&#93;</a></sup><sup id="cite_ref-fineman16_19-2" class="reference"><a href="#cite_note-fineman16-19">&#91;19&#93;</a></sup><sup id="cite_ref-lumbrosolerouic39_42-0" class="reference"><a href="#cite_note-lumbrosolerouic39-42">&#91;42&#93;</a></sup> Ciliary body, iris, and ring melanomas tend to cause IOP elevation by direct invasion of the anterior chamber angle or pigment dispersion.<sup id="cite_ref-shields8_8-11" class="reference"><a href="#cite_note-shields8-8">&#91;8&#93;</a></sup><sup id="cite_ref-krohn17_12-4" class="reference"><a href="#cite_note-krohn17-12">&#91;12&#93;</a></sup> 
</p><p>Angle closure glaucoma is also common and can occur from a variety of mechanisms. It can be from neovascularization (usually with chronic retinal detachment), anterior displacement of the lens-iris diaphragm from large posterior segment tumors, and/or synechial angle closure.<sup id="cite_ref-radcliffe1_1-8" class="reference"><a href="#cite_note-radcliffe1-1">&#91;1&#93;</a></sup><sup id="cite_ref-shields2_2-6" class="reference"><a href="#cite_note-shields2-2">&#91;2&#93;</a></sup><sup id="cite_ref-shields8_8-12" class="reference"><a href="#cite_note-shields8-8">&#91;8&#93;</a></sup>
</p>
<h4><span class="mw-headline" id="Retinoblastoma"><b>Retinoblastoma</b></span></h4>
<p>Retinoblastoma is the most common primary intraocular tumor in children and most commonly presents with strabismus and leukocoria. Patients also rarely can have a red, painful eye either from inflammation or elevated IOP.<sup id="cite_ref-deleon40_43-0" class="reference"><a href="#cite_note-deleon40-43">&#91;43&#93;</a></sup>
</p><p>In a large retrospective study it was shown that 17% of retinoblastoma patients had elevation of IOP.<sup id="cite_ref-shields8_8-13" class="reference"><a href="#cite_note-shields8-8">&#91;8&#93;</a></sup> The majority of pressure elevation is secondary to neovascularization followed by displacement of the iris-lens diaphragm.<sup id="cite_ref-shields8_8-14" class="reference"><a href="#cite_note-shields8-8">&#91;8&#93;</a></sup><sup id="cite_ref-deleon40_43-1" class="reference"><a href="#cite_note-deleon40-43">&#91;43&#93;</a></sup> Other less common causes of secondary glaucoma include tumor seeding of the anterior chamber angle, uveitis, and vitreous hemorrhage.
</p>
<h4><span class="mw-headline" id="Other_Tumors"><b>Other Tumors</b></span></h4>
<ul><li>Medulloepithelioma. A congenital embryonal tumor of the ciliary body, these tumors cause IOP elevation in just under half of patients usually through direct tumor invasion of the angle or neovascularization.<sup id="cite_ref-shields8_8-15" class="reference"><a href="#cite_note-shields8-8">&#91;8&#93;</a></sup><sup id="cite_ref-kaliki42_44-0" class="reference"><a href="#cite_note-kaliki42-44">&#91;44&#93;</a></sup></li></ul>
<ul><li>Iris melanocytoma. These tumors cause elevated IOP through pigmentary or melanomalytic glaucoma.<sup id="cite_ref-shields8_8-16" class="reference"><a href="#cite_note-shields8-8">&#91;8&#93;</a></sup><sup id="cite_ref-de18_16-1" class="reference"><a href="#cite_note-de18-16">&#91;16&#93;</a></sup><sup id="cite_ref-demirci43_45-0" class="reference"><a href="#cite_note-demirci43-45">&#91;45&#93;</a></sup></li></ul>
<ul><li>Multiple Myeloma are a malignant proliferation of plasma cells, and have been reported to cause secondary glaucoma by anterior chamber angle invasion or secondary angle-closure.<sup id="cite_ref-chin21_39-1" class="reference"><a href="#cite_note-chin21-39">&#91;39&#93;</a></sup></li></ul>
<ul><li>Juvenile Xanthogranuloma is a benign skin disorder that presents with cutaneous lesions, can have iris lesions, spontaneous hyphema, uveitis and secondary glaucoma.<sup id="cite_ref-chang44_25-1" class="reference"><a href="#cite_note-chang44-25">&#91;25&#93;</a></sup> Cellular infiltration of the angle, hyphema, or peripheral anterior synechiae and angle closure lead to secondary glaucoma.<sup id="cite_ref-vendal45_46-0" class="reference"><a href="#cite_note-vendal45-46">&#91;46&#93;</a></sup></li></ul>
<h1><span class="mw-headline" id="Management">Management</span></h1>
<p>For intraocular tumors with secondary glaucoma, elimination of the viable tumor cells is of primary importance. Control of IOP can be done either medically or surgically. 
</p>
<h2><span class="mw-headline" id="Medical_therapy">Medical therapy</span></h2>
<p>Treatment of the secondary glaucoma should begin with topical eye drops (alpha-agonists, beta-blockers and carbonic anhydrase inhibitors) which decrease aqueous humor production. If the pressure remains uncontrolled on topical medication then oral hypotensive agents like acetazolamide or methazolamide should be tried.  Prostaglandin analogues are not strictly contradicted, however, there is controversy over whether this class of medication should be given in ocular tumor patients, as a theoretical concern for metastasis due to the increased uveoscleral outflow is present.<sup id="cite_ref-deleon40_43-2" class="reference"><a href="#cite_note-deleon40-43">&#91;43&#93;</a></sup> 
</p><p>For metastases with multiple lesions in the eye, systemically chemotherapy can play a large role. In eyes that have poor visual potential and elevated pressure, treatment for secondary glaucoma should only be given if pain is present.
</p>
<h2><span class="mw-headline" id="Surgery">Surgery</span></h2>
<p>Surgical intervention should only be considered if the patient failed more conservative treatment options. Successful en-bloc resections of the iris and ciliary body tumors have been reported with large tectonic corneoscleral grafts. These surgeries do carry a risk of hypotony if more than 5 clock hours are removed.<sup id="cite_ref-rennie51_47-0" class="reference"><a href="#cite_note-rennie51-47">&#91;47&#93;</a></sup> Transscleral cyclophotocoagulation or cryotherapy to the ciliary body offer less invasive ways to control IOP.<sup id="cite_ref-radcliffe1_1-9" class="reference"><a href="#cite_note-radcliffe1-1">&#91;1&#93;</a></sup><sup id="cite_ref-lumbrosolerouic39_42-1" class="reference"><a href="#cite_note-lumbrosolerouic39-42">&#91;42&#93;</a></sup><sup id="cite_ref-deleon40_43-3" class="reference"><a href="#cite_note-deleon40-43">&#91;43&#93;</a></sup>
</p><p>Incisional glaucoma surgery, including filtration procedures and aqueous tube shunts, are generally contraindicated, except in cases of metastases, due to the potential risk of facilitating tumor spread outside of the globe.<sup id="cite_ref-radcliffe1_1-10" class="reference"><a href="#cite_note-radcliffe1-1">&#91;1&#93;</a></sup><sup id="cite_ref-feinstein38_35-2" class="reference"><a href="#cite_note-feinstein38-35">&#91;35&#93;</a></sup><sup id="cite_ref-deleon40_43-4" class="reference"><a href="#cite_note-deleon40-43">&#91;43&#93;</a></sup><sup id="cite_ref-kaliki42_44-1" class="reference"><a href="#cite_note-kaliki42-44">&#91;44&#93;</a></sup><sup id="cite_ref-grossniklaus31_48-0" class="reference"><a href="#cite_note-grossniklaus31-48">&#91;48&#93;</a></sup> Minimally invasive glaucoma procedures may play a role, however the risk for tumor spread remains.<sup id="cite_ref-demirci43_45-1" class="reference"><a href="#cite_note-demirci43-45">&#91;45&#93;</a></sup> 
</p><p>Sometimes treatment of the underlying tumors with plaque brachytherapy, external beam radiation, chemotherapy, or radiation can improve the IOP. For certain tumors like large uveal melanomas, retinoblastoma, or a blind painful eye primary enucleation may be the appropriate option.
</p>
<h2><span class="mw-headline" id="Complications">Complications</span></h2>
<p>A significant number of patients will develop <a href="/Neovascular_Glaucoma" title="Neovascular Glaucoma">neovascular glaucoma (NVG)</a> following treatment of the original tumor with brachytherapy and proton beam radiation.<sup id="cite_ref-bollinger5_5-2" class="reference"><a href="#cite_note-bollinger5-5">&#91;5&#93;</a></sup><sup id="cite_ref-bergmann29_24-1" class="reference"><a href="#cite_note-bergmann29-24">&#91;24&#93;</a></sup><sup id="cite_ref-chang44_25-2" class="reference"><a href="#cite_note-chang44-25">&#91;25&#93;</a></sup><sup id="cite_ref-albert46_26-1" class="reference"><a href="#cite_note-albert46-26">&#91;26&#93;</a></sup><sup id="cite_ref-naumann48_27-1" class="reference"><a href="#cite_note-naumann48-27">&#91;27&#93;</a></sup><sup id="cite_ref-gragoudas26_49-0" class="reference"><a href="#cite_note-gragoudas26-49">&#91;49&#93;</a></sup> Heightened vigilance and appropriate follow-up in these patients is key. Other systemic medications including docetaxel, paclitaxel and imatinib as well as intravitreal rituximab/methotrexate have been reported to elevate IOP.<sup id="cite_ref-fabreguillevin53_17-2" class="reference"><a href="#cite_note-fabreguillevin53-17">&#91;17&#93;</a></sup><sup id="cite_ref-van36_31-2" class="reference"><a href="#cite_note-van36-31">&#91;31&#93;</a></sup><sup id="cite_ref-fraunfelder52_50-0" class="reference"><a href="#cite_note-fraunfelder52-50">&#91;50&#93;</a></sup>
</p>
<h2><span class="mw-headline" id="Prognosis">Prognosis</span></h2>
<p>Prognosis is highly variable and depends upon the type of tumor, the degree of ocular involvement, and the treatment received. The primary goal for any treatment is to control the tumor first and then control the IOP. Management of any intraocular tumor must be done concurrently with an oncologist to treat systemic diseases as well.
</p>
<h1><span class="mw-headline" id="References">References</span></h1>
<div class="mw-references-wrap mw-references-columns"><ol class="references">
<li id="cite_note-radcliffe1-1"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-radcliffe1_1-0">1.00</a></sup> <sup><a href="#cite_ref-radcliffe1_1-1">1.01</a></sup> <sup><a href="#cite_ref-radcliffe1_1-2">1.02</a></sup> <sup><a href="#cite_ref-radcliffe1_1-3">1.03</a></sup> <sup><a href="#cite_ref-radcliffe1_1-4">1.04</a></sup> <sup><a href="#cite_ref-radcliffe1_1-5">1.05</a></sup> <sup><a href="#cite_ref-radcliffe1_1-6">1.06</a></sup> <sup><a href="#cite_ref-radcliffe1_1-7">1.07</a></sup> <sup><a href="#cite_ref-radcliffe1_1-8">1.08</a></sup> <sup><a href="#cite_ref-radcliffe1_1-9">1.09</a></sup> <sup><a href="#cite_ref-radcliffe1_1-10">1.10</a></sup></span> <span class="reference-text"> Radcliffe NM, Finger PT. Eye cancer related glaucoma: current concepts. Surv Ophthalmol. 2009;54(1):47-73.</span>
</li>
<li id="cite_note-shields2-2"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-shields2_2-0">2.0</a></sup> <sup><a href="#cite_ref-shields2_2-1">2.1</a></sup> <sup><a href="#cite_ref-shields2_2-2">2.2</a></sup> <sup><a href="#cite_ref-shields2_2-3">2.3</a></sup> <sup><a href="#cite_ref-shields2_2-4">2.4</a></sup> <sup><a href="#cite_ref-shields2_2-5">2.5</a></sup> <sup><a href="#cite_ref-shields2_2-6">2.6</a></sup></span> <span class="reference-text"> Shields CL, Materin MA, Shields JA et al. Factors associated with elevated intraocular pressure in eyes with iris melanoma. Br. J Ophthalmol. 2001;85(6):666-9.</span>
</li>
<li id="cite_note-ferry3-3"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-ferry3_3-0">3.0</a></sup> <sup><a href="#cite_ref-ferry3_3-1">3.1</a></sup> <sup><a href="#cite_ref-ferry3_3-2">3.2</a></sup> <sup><a href="#cite_ref-ferry3_3-3">3.3</a></sup> <sup><a href="#cite_ref-ferry3_3-4">3.4</a></sup> <sup><a href="#cite_ref-ferry3_3-5">3.5</a></sup> <sup><a href="#cite_ref-ferry3_3-6">3.6</a></sup></span> <span class="reference-text"> Ferry AP, Font RL. Carcinoma metastatic to the eye and orbit II. A clinicopathological study of 26 patients with carcinoma metastatic to the anterior segment of the eye. Arch Ophthalmol. 1975;93(7):472-82.	</span>
</li>
<li id="cite_note-ferry4-4"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-ferry4_4-0">4.0</a></sup> <sup><a href="#cite_ref-ferry4_4-1">4.1</a></sup> <sup><a href="#cite_ref-ferry4_4-2">4.2</a></sup> <sup><a href="#cite_ref-ferry4_4-3">4.3</a></sup> <sup><a href="#cite_ref-ferry4_4-4">4.4</a></sup></span> <span class="reference-text"> Ferry AP, Font RL. Carcinoma metastatic to the eye and orbit II. A clinicopathological study of 26 patients with carcinoma metastatic to the anterior segment of the eye. Arch Ophthalmol. 1975;93(7):472-82.	</span>
</li>
<li id="cite_note-bollinger5-5"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-bollinger5_5-0">5.0</a></sup> <sup><a href="#cite_ref-bollinger5_5-1">5.1</a></sup> <sup><a href="#cite_ref-bollinger5_5-2">5.2</a></sup></span> <span class="reference-text">  Bollinger, Kathryn, Annapurna Singh, and Arun D. Singh. "Glaucoma and Intraocular Tumors." Ed. Tarek M. Shaarawy, Mark B. Sherwood, Roger A. Hitchings, and Jonathan G. Crowston. Glaucoma: Medical Diagnosis and Therapy. Philadelphia: Saunders/Elsevier, 2009. 441-47. Print.</span>
</li>
<li id="cite_note-nelson6-6"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-nelson6_6-0">6.0</a></sup> <sup><a href="#cite_ref-nelson6_6-1">6.1</a></sup> <sup><a href="#cite_ref-nelson6_6-2">6.2</a></sup> <sup><a href="#cite_ref-nelson6_6-3">6.3</a></sup> <sup><a href="#cite_ref-nelson6_6-4">6.4</a></sup></span> <span class="reference-text"> Nelson CC, Hertzberg BS, Klintworth GK. A histopathologic study of 716 unselected eyes in patients with cancer at the time of death. Am J Ophthalmol. 1983;95:788-793.</span>
</li>
<li id="cite_note-shields7-7"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-shields7_7-0">7.0</a></sup> <sup><a href="#cite_ref-shields7_7-1">7.1</a></sup> <sup><a href="#cite_ref-shields7_7-2">7.2</a></sup> <sup><a href="#cite_ref-shields7_7-3">7.3</a></sup> <sup><a href="#cite_ref-shields7_7-4">7.4</a></sup> <sup><a href="#cite_ref-shields7_7-5">7.5</a></sup> <sup><a href="#cite_ref-shields7_7-6">7.6</a></sup></span> <span class="reference-text"> Shields CL, Shields JA, Gross NE, Schwartz GP, Lally SE. Survey of 520 eyes with uveal metastases. Ophthalmology. 1996 Aug; 104(8):1265-76.</span>
</li>
<li id="cite_note-shields8-8"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-shields8_8-0">8.00</a></sup> <sup><a href="#cite_ref-shields8_8-1">8.01</a></sup> <sup><a href="#cite_ref-shields8_8-2">8.02</a></sup> <sup><a href="#cite_ref-shields8_8-3">8.03</a></sup> <sup><a href="#cite_ref-shields8_8-4">8.04</a></sup> <sup><a href="#cite_ref-shields8_8-5">8.05</a></sup> <sup><a href="#cite_ref-shields8_8-6">8.06</a></sup> <sup><a href="#cite_ref-shields8_8-7">8.07</a></sup> <sup><a href="#cite_ref-shields8_8-8">8.08</a></sup> <sup><a href="#cite_ref-shields8_8-9">8.09</a></sup> <sup><a href="#cite_ref-shields8_8-10">8.10</a></sup> <sup><a href="#cite_ref-shields8_8-11">8.11</a></sup> <sup><a href="#cite_ref-shields8_8-12">8.12</a></sup> <sup><a href="#cite_ref-shields8_8-13">8.13</a></sup> <sup><a href="#cite_ref-shields8_8-14">8.14</a></sup> <sup><a href="#cite_ref-shields8_8-15">8.15</a></sup> <sup><a href="#cite_ref-shields8_8-16">8.16</a></sup></span> <span class="reference-text"> Shields CL, Shields JA, Shields MB, Augsburger JJ. Prevalence and mechanisms of secondary intraocular pressure elevation in eyes with intraocular tumors. Ophthalmology. 1987;94(7):839-846.</span>
</li>
<li id="cite_note-shields9-9"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-shields9_9-0">9.0</a></sup> <sup><a href="#cite_ref-shields9_9-1">9.1</a></sup> <sup><a href="#cite_ref-shields9_9-2">9.2</a></sup> <sup><a href="#cite_ref-shields9_9-3">9.3</a></sup></span> <span class="reference-text"> Shields CL, Materin MA, Shields JA et al. Factors associated with elevated intraocular pressure in eyes with iris melanoma. Br. J Ophthalmol. 2001;85(6):666-9.</span>
</li>
<li id="cite_note-shields10-10"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-shields10_10-0">10.0</a></sup> <sup><a href="#cite_ref-shields10_10-1">10.1</a></sup> <sup><a href="#cite_ref-shields10_10-2">10.2</a></sup></span> <span class="reference-text"> Shields CL et al. Iris Metastasis From Systemic Cancer in 104 Patients: The 2014 Jerry A. Shields Lecture. Cornea. 2015 Jan;34 (1).</span>
</li>
<li id="cite_note-shields11-11"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-shields11_11-0">11.0</a></sup> <sup><a href="#cite_ref-shields11_11-1">11.1</a></sup> <sup><a href="#cite_ref-shields11_11-2">11.2</a></sup> <sup><a href="#cite_ref-shields11_11-3">11.3</a></sup></span> <span class="reference-text"> Shields CL, Kaliki S, Furuta M, et al. Iris melanoma features and prognosis in children and adults in 317 patients. J Am Assoc Pediatr Ophthalmol Strabismus 2012;16:10-6. </span>
</li>
<li id="cite_note-krohn17-12"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-krohn17_12-0">12.0</a></sup> <sup><a href="#cite_ref-krohn17_12-1">12.1</a></sup> <sup><a href="#cite_ref-krohn17_12-2">12.2</a></sup> <sup><a href="#cite_ref-krohn17_12-3">12.3</a></sup> <sup><a href="#cite_ref-krohn17_12-4">12.4</a></sup></span> <span class="reference-text"> Krohn J, Mørk SJ. Acute glaucoma caused by massive pigment dispersion from necrotic choroidal melanoma. Can J Ophthalmol. 2010 Aug;45(4):417-8.  </span>
</li>
<li id="cite_note-Demirci13-13"><span class="mw-cite-backlink"><a href="#cite_ref-Demirci13_13-0">↑</a></span> <span class="reference-text">Demirci H, Shields CL, Shields JA, Honavar SG, Eagle RC. Ring Melanoma of the Ciliary Body. Report of Twenty-Three Patients. Retina 22:689-706, 2002.</span>
</li>
<li id="cite_note-mcmenamin12-14"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-mcmenamin12_14-0">14.0</a></sup> <sup><a href="#cite_ref-mcmenamin12_14-1">14.1</a></sup> <sup><a href="#cite_ref-mcmenamin12_14-2">14.2</a></sup> <sup><a href="#cite_ref-mcmenamin12_14-3">14.3</a></sup> <sup><a href="#cite_ref-mcmenamin12_14-4">14.4</a></sup></span> <span class="reference-text"> McMenamin PG, Lee WR. Ultrastructural pathology of melanomalytic glaucoma. Br J Ophthalmol. 1986 Dec;70(12):895-906.</span>
</li>
<li id="cite_note-lee14-15"><span class="mw-cite-backlink"><a href="#cite_ref-lee14_15-0">↑</a></span> <span class="reference-text">Lee V, Cree IA, Hungerford JL. Ring Melanoma- A Rare Cause of Refractory Glaucoma. Br J Ophthalmol. 1999;84:194-198.</span>
</li>
<li id="cite_note-de18-16"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-de18_16-0">16.0</a></sup> <sup><a href="#cite_ref-de18_16-1">16.1</a></sup></span> <span class="reference-text"> de A Alves LF, Fernandes BF, Menezes MS, Ribeiro AS, Leal MM, Burnier JV, Burnier MN Jr. Management of glaucoma in an eye with diffuse iris melanocytoma.  Br J Ophthalmol. 2011 Oct;95(10):1471, 1479.</span>
</li>
<li id="cite_note-fabreguillevin53-17"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-fabreguillevin53_17-0">17.0</a></sup> <sup><a href="#cite_ref-fabreguillevin53_17-1">17.1</a></sup> <sup><a href="#cite_ref-fabreguillevin53_17-2">17.2</a></sup></span> <span class="reference-text">  Fabre-Guillevin E, Tchen N, Anibali-Charpiat MF, Calluaud L, Ravaud A.  Taxane-induced glaucoma. Lancet. 1999 Oct 2;354(9185):1181-2.</span>
</li>
<li id="cite_note-yanoff15-18"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-yanoff15_18-0">18.0</a></sup> <sup><a href="#cite_ref-yanoff15_18-1">18.1</a></sup> <sup><a href="#cite_ref-yanoff15_18-2">18.2</a></sup> <sup><a href="#cite_ref-yanoff15_18-3">18.3</a></sup></span> <span class="reference-text"> Yanoff M, Scheie HG. Melanomalytic glaucoma. Report of a case. Arch Ophthalmol. 1970 Oct;84(4):471-3.</span>
</li>
<li id="cite_note-fineman16-19"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-fineman16_19-0">19.0</a></sup> <sup><a href="#cite_ref-fineman16_19-1">19.1</a></sup> <sup><a href="#cite_ref-fineman16_19-2">19.2</a></sup></span> <span class="reference-text"> Fineman MS, Eagle RC Jr, Shields JA, Shields CL, De Potter P.  Melanocytomalytic glaucoma in eyes with necrotic iris melanocytoma.  Ophthalmology. 1998 Mar;105(3):492-6.</span>
</li>
<li id="cite_note-matano35-20"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-matano35_20-0">20.0</a></sup> <sup><a href="#cite_ref-matano35_20-1">20.1</a></sup> <sup><a href="#cite_ref-matano35_20-2">20.2</a></sup> <sup><a href="#cite_ref-matano35_20-3">20.3</a></sup></span> <span class="reference-text"> Matano S, Ohta T, Nakamura S, et al. Leukemic hypopyon in acute myelogenous leukemia. Ann Hematol. 2000;79(8): 455--8</span>
</li>
<li id="cite_note-j.C3.B8rgensen19-21"><span class="mw-cite-backlink"><a href="#cite_ref-j.C3.B8rgensen19_21-0">↑</a></span> <span class="reference-text">Jørgensen JS, Guthoff R. [The role of episcleral venous pressure in the development of secondary glaucomas]. Klin Monbl Augenheilkd. 1988 Nov;193(5):471-5.</span>
</li>
<li id="cite_note-girkin47-22"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-girkin47_22-0">22.0</a></sup> <sup><a href="#cite_ref-girkin47_22-1">22.1</a></sup> <sup><a href="#cite_ref-girkin47_22-2">22.2</a></sup></span> <span class="reference-text"> Girkin CA, Goldberg I, Mansberger SL, Shields JA, Shields CL. Management of iris melanoma with secondary glaucoma. J Glaucoma. 2002 Feb;11(1):71-4.</span>
</li>
<li id="cite_note-garrison20-23"><span class="mw-cite-backlink"><a href="#cite_ref-garrison20_23-0">↑</a></span> <span class="reference-text">Garrison LM, Christensen RE, Allen RA. Angle-closure glaucoma from metastatic carcinoma. Am J Ophthalmol. 1967 Mar;63(3):503-7.</span>
</li>
<li id="cite_note-bergmann29-24"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-bergmann29_24-0">24.0</a></sup> <sup><a href="#cite_ref-bergmann29_24-1">24.1</a></sup></span> <span class="reference-text"> Bergmann U, Guthoff R. [Ultrasound biomicroscopy for evaluation of space-occupying lesions of the anterior eye segment. Initial results].  Ophthalmologe. 1995 Dec;92(6):844-8.</span>
</li>
<li id="cite_note-chang44-25"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-chang44_25-0">25.0</a></sup> <sup><a href="#cite_ref-chang44_25-1">25.1</a></sup> <sup><a href="#cite_ref-chang44_25-2">25.2</a></sup></span> <span class="reference-text"> Chang MW, Frieden IJ, Good W. The risk intraocular juvenile xanthogranuloma: survey of current practices and assessment of risk. J Am Acad Dermatol. 1996 Mar;34(3):445-9.</span>
</li>
<li id="cite_note-albert46-26"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-albert46_26-0">26.0</a></sup> <sup><a href="#cite_ref-albert46_26-1">26.1</a></sup></span> <span class="reference-text"> Albert DM, Gangnon RE, Zimbric ML, Damico CM, Fisher MR, Gleiser J, Grossniklaus HE, Green WR. A study of iridectomy histopathologic features of latanoprost- and non-latanoprost-treated patients. Arch Ophthalmol. 2004 Nov;122(11):1680-5.</span>
</li>
<li id="cite_note-naumann48-27"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-naumann48_27-0">27.0</a></sup> <sup><a href="#cite_ref-naumann48_27-1">27.1</a></sup></span> <span class="reference-text"> Naumann GO, Rummelt V. Block excision of tumors of the anterior uvea. Report on 68 consecutive patients. Ophthalmology. 1996 Dec;103(12):2017-27.</span>
</li>
<li id="cite_note-gunduz22-28"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-gunduz22_28-0">28.0</a></sup> <sup><a href="#cite_ref-gunduz22_28-1">28.1</a></sup></span> <span class="reference-text">  Gündüz K, Shields JA, Shields CL, Eagle RC Jr. Cutaneous melanoma metastatic to the vitreous cavity. Ophthalmology. 1998 Apr;105(4):600-5.</span>
</li>
<li id="cite_note-puusaari25-29"><span class="mw-cite-backlink"><a href="#cite_ref-puusaari25_29-0">↑</a></span> <span class="reference-text"> Puusaari I, Heikkonen J, Kivelä T. Ocular complications after iodine brachytherapy for large uveal melanomas. Ophthalmology. 2004 Sep;111(9):1768-77.</span>
</li>
<li id="cite_note-schuman34-30"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-schuman34_30-0">30.0</a></sup> <sup><a href="#cite_ref-schuman34_30-1">30.1</a></sup></span> <span class="reference-text"> Schuman JS, Wang N, Eisenberg DL. Leukemic glaucoma: the effects on outflow facility of chronic lymphocytic leukemia lymphocytes. Exp Eye Res. 1995;61(5):609-17.</span>
</li>
<li id="cite_note-van36-31"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-van36_31-0">31.0</a></sup> <sup><a href="#cite_ref-van36_31-1">31.1</a></sup> <sup><a href="#cite_ref-van36_31-2">31.2</a></sup></span> <span class="reference-text"> van Oterendorp C, Ness T, Illerhaus G, Neuburger M, Jordan JF. The trabectome as treatment option in secondary glaucoma due to intraocular lymphoma. J Glaucoma. 2014 Sep;23(7):482-4</span>
</li>
<li id="cite_note-ellsworth23-32"><span class="mw-cite-backlink"><a href="#cite_ref-ellsworth23_32-0">↑</a></span> <span class="reference-text"> Ellsworth RM. The practical management of retinoblastoma. Trans Am Ophthalmol Soc. 1969;67:462-534.</span>
</li>
<li id="cite_note-conway24-33"><span class="mw-cite-backlink"><a href="#cite_ref-conway24_33-0">↑</a></span> <span class="reference-text"> Conway RM, Poothullil AM, Daftari IK, Weinberg V, Chung JE, O'Brien JM.  Estimates of ocular and visual retention following treatment of extra-large uveal melanomas by proton beam radiotherapy. Arch Ophthalmol. 2006 Jun;124(6):838-43.</span>
</li>
<li id="cite_note-sullivan37-34"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-sullivan37_34-0">34.0</a></sup> <sup><a href="#cite_ref-sullivan37_34-1">34.1</a></sup></span> <span class="reference-text"> Sullivan SF, Dallow RI. Intraocular reticulum cell sarcoma: its dramatic response to systemic chemotherapy and its angiogenic potential. Ann Ophthalmol.  1977 Apr;9(4):401-6.</span>
</li>
<li id="cite_note-feinstein38-35"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-feinstein38_35-0">35.0</a></sup> <sup><a href="#cite_ref-feinstein38_35-1">35.1</a></sup> <sup><a href="#cite_ref-feinstein38_35-2">35.2</a></sup></span> <span class="reference-text"> Feinstein E, Kaliki S, Shields CL, Ehya H, Shields JA. Choroidal metastasis from leiomyosarcoma in two cases. Oman J Ophthalmol. 2014 Jan;7(1):19-21.</span>
</li>
<li id="cite_note-velez33-36"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-velez33_36-0">36.0</a></sup> <sup><a href="#cite_ref-velez33_36-1">36.1</a></sup> <sup><a href="#cite_ref-velez33_36-2">36.2</a></sup></span> <span class="reference-text"> Velez G, de Smet MD, Whitcup SM, Robinson M, Nussenblatt RB, Chan CC. Iris involvement in primary intraocular lymphoma: report of two cases and review of the literature. Surv Ophthalmol. 2000 May-Jun;44(6):518-26.</span>
</li>
<li id="cite_note-mashayekhi32-37"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-mashayekhi32_37-0">37.0</a></sup> <sup><a href="#cite_ref-mashayekhi32_37-1">37.1</a></sup> <sup><a href="#cite_ref-mashayekhi32_37-2">37.2</a></sup> <sup><a href="#cite_ref-mashayekhi32_37-3">37.3</a></sup></span> <span class="reference-text"> Mashayekhi A, Shields CL, Shields JA. Iris involvement by lymphoma: a review of 13 cases. Clin Experiment Ophthalmol. 2013 Jan-Feb;41(1):19-26.</span>
</li>
<li id="cite_note-cooper27-38"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-cooper27_38-0">38.0</a></sup> <sup><a href="#cite_ref-cooper27_38-1">38.1</a></sup> <sup><a href="#cite_ref-cooper27_38-2">38.2</a></sup></span> <span class="reference-text"> Cooper EL, Riker JL. Malignant Lymphoma of the Uveal Tract. Am J Ophthalmol. 1951 Aug;34(8):1153-8.</span>
</li>
<li id="cite_note-chin21-39"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-chin21_39-0">39.0</a></sup> <sup><a href="#cite_ref-chin21_39-1">39.1</a></sup></span> <span class="reference-text"> Chin KJ, Kempin S, Milman T, Finger PT. Ocular manifestations of multiple myeloma: three cases and a review of the literature. Optometry. 2011 Apr;82(4):224-30.</span>
</li>
<li id="cite_note-wanner28-40"><span class="mw-cite-backlink"><a href="#cite_ref-wanner28_40-0">↑</a></span> <span class="reference-text"> Wanner JB, Pasquale LR. Glaucomas secondary to intraocular melanomas. Semin Ophthalmol. 2006 Jul-Sep;21(3):181-9.</span>
</li>
<li id="cite_note-faulknerjones30-41"><span class="mw-cite-backlink"><a href="#cite_ref-faulknerjones30_41-0">↑</a></span> <span class="reference-text">  Faulkner-Jones BE, Foster WJ, Harbour JW, Smith ME, Dávila RM. Fine needle aspiration biopsy with adjunct immunohistochemistry in intraocular tumor management. Acta Cytol. 2005 May-Jun;49(3):297-308.</span>
</li>
<li id="cite_note-lumbrosolerouic39-42"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-lumbrosolerouic39_42-0">42.0</a></sup> <sup><a href="#cite_ref-lumbrosolerouic39_42-1">42.1</a></sup></span> <span class="reference-text">  Lumbroso-Le Rouic L, Charif Chefchaouni M, Levy C, Plancher C, Dendale R, Asselain B, Solignac S, Mazal A, Desjardins L. 125I plaque brachytherapy for anterior uveal melanomas. Eye (Lond). 2004 Sep;18(9):911-6.</span>
</li>
<li id="cite_note-deleon40-43"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-deleon40_43-0">43.0</a></sup> <sup><a href="#cite_ref-deleon40_43-1">43.1</a></sup> <sup><a href="#cite_ref-deleon40_43-2">43.2</a></sup> <sup><a href="#cite_ref-deleon40_43-3">43.3</a></sup> <sup><a href="#cite_ref-deleon40_43-4">43.4</a></sup></span> <span class="reference-text"> de Leon JM, Walton DS, Latina MA, Mercado GV. Glaucoma in retinoblastoma.  Semin Ophthalmol. 2005 Oct-Dec;20(4):217-22.</span>
</li>
<li id="cite_note-kaliki42-44"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-kaliki42_44-0">44.0</a></sup> <sup><a href="#cite_ref-kaliki42_44-1">44.1</a></sup></span> <span class="reference-text"> Kaliki S, Shields CL, Eagle RC Jr, Vemuganti GK, Almeida A, Manjandavida FP, Mulay K, Honavar SG, Shields JA. Ciliary body medulloepithelioma: analysis of 41 cases. Ophthalmology. 2013 Dec;120(12):2552-9. </span>
</li>
<li id="cite_note-demirci43-45"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-demirci43_45-0">45.0</a></sup> <sup><a href="#cite_ref-demirci43_45-1">45.1</a></sup></span> <span class="reference-text"> Demirci H, Mashayekhi A, Shields CL, Eagle RC Jr, Shields JA. Iris melanocytoma: clinical features and natural course in 47 cases. Am J Ophthalmol.  2005 Mar;139(3):468-75.</span>
</li>
<li id="cite_note-vendal45-46"><span class="mw-cite-backlink"><a href="#cite_ref-vendal45_46-0">↑</a></span> <span class="reference-text"> Vendal Z, Walton D, Chen T. Glaucoma in juvenile xanthogranuloma. Semin Ophthalmol. 2006 Jul-Sep;21(3):191-4.</span>
</li>
<li id="cite_note-rennie51-47"><span class="mw-cite-backlink"><a href="#cite_ref-rennie51_47-0">↑</a></span> <span class="reference-text">Rennie IG. Clinically important ocular reactions to systemic drug therapy. Drug Saf. 1993 Sep;9(3):196-211.</span>
</li>
<li id="cite_note-grossniklaus31-48"><span class="mw-cite-backlink"><a href="#cite_ref-grossniklaus31_48-0">↑</a></span> <span class="reference-text"> Grossniklaus HE, Brown RH, Stulting RD, Blasberg RD. Iris melanoma seeding through a trabeculectomy site. Arch Ophthalmol. 1990 Sep;108(9):1287-90.</span>
</li>
<li id="cite_note-gragoudas26-49"><span class="mw-cite-backlink"><a href="#cite_ref-gragoudas26_49-0">↑</a></span> <span class="reference-text">Gragoudas ES, Seddon JM, Egan K, Glynn R, Munzenrider J, Austin-Seymour M, Goitein M, Verhey L, Urie M, Koehler A. Long-term results of proton beam irradiated uveal melanomas. Ophthalmology. 1987 Apr;94(4):349-53."</span>
</li>
<li id="cite_note-fraunfelder52-50"><span class="mw-cite-backlink"><a href="#cite_ref-fraunfelder52_50-0">↑</a></span> <span class="reference-text"> Fraunfelder FW, Solomon J, Druker BJ, Esmaeli B, Kuyl J. Ocular side-effects associated with imatinib mesylate (Gleevec). J Ocul Pharmacol Ther. 2003 Aug;19(4):371-5.</span>
</li>
</ol></div>
<ol>

<li value="52">Pasternak S, Erwenne CM, Nicolela MT. Subconjunctival spread of ciliary body melanoma after glaucoma filtering surgery: a clinicopathological case report. Can J Ophthalmol. 2005 Feb;40(1):69-71.  </li>
<li>Boonyaleephan S. Drug-induced secondary glaucoma. J Med Assoc Thai. 2010 Feb;93 Suppl 2:S118-22.</li>
<li>Sharkawi E, Oleszczuk JD, Bergin C, Zografos L. Baerveldt shunts in the treatment of glaucoma secondary to anterior uveal melanoma and proton beam radiotherapy. Br J Ophthalmol. 2012 Aug;96(8):1104-7.</li>
<li>Mantel I, Schalenbourg A, Bergin C, Petrovic A, Weber DC, Zografos L.  Prophylactic use of bevacizumab to avoid anterior segment neovascularization following proton therapy for uveal melanoma. Am J Ophthalmol. 2014 Oct;158(4):693-701.</li>
</ol>
<!-- 
NewPP limit report
Cached time: 20230306035154
Cache expiry: 86400
Dynamic content: false
Complications: [my_variables_no_cache]
[SMW] In‐text annotation parser time: 0.001 seconds
CPU time usage: 0.354 seconds
Real time usage: 2.898 seconds
Preprocessor visited node count: 1642/1000000
Post‐expand include size: 6501/2097152 bytes
Template argument size: 1462/2097152 bytes
Highest expansion depth: 11/40
Expensive parser function count: 0/100
Unstrip recursion depth: 0/20
Unstrip post‐expand size: 39370/5000000 bytes
-->
<!--
Transclusion expansion time report (%,ms,calls,template)
100.00%  809.819      1 Template:Article
100.00%  809.819      1 -total
 97.59%  790.326      4 Template:Infobox_section
 41.76%  338.174      8 Template:UserLookup
  5.63%   45.589      1 Template:Review_expired
  0.72%    5.852      1 Template:Infobox_end
  0.17%    1.337      1 Template:Get_active_contest
  0.12%    0.948      1 Template:Infobox_begin
-->
</div></div><div class="printfooter">
Retrieved from "<a dir="ltr" href="https://eyewiki.org/w/index.php?title=Glaucoma_Secondary_to_Intraocular_Tumors&amp;oldid=86663">https://eyewiki.org/w/index.php?title=Glaucoma_Secondary_to_Intraocular_Tumors&amp;oldid=86663</a>"</div>

						<!-- end body text -->
						<!-- data blocks which should go somewhere after the body text, but not before the catlinks block-->
						<div id='mw-data-after-content'>
	<div class="mw-cookiewarning-container"><div class="mw-cookiewarning-text"><span>The Academy uses cookies to analyze performance and provide relevant personalized content to users of our website.</span></div><form method="POST"><div class='oo-ui-layout oo-ui-horizontalLayout'><span aria-disabled='false' class='oo-ui-widget oo-ui-widget-enabled oo-ui-buttonElement oo-ui-buttonElement-framed oo-ui-labelElement oo-ui-flaggedElement-progressive oo-ui-buttonWidget'><a role='button' tabindex='0' aria-disabled='false' href='https://www.aao.org/privacy-policy' rel='nofollow' class='oo-ui-buttonElement-button'><span class='oo-ui-iconElement-icon oo-ui-iconElement-noIcon oo-ui-image-progressive'></span><span class='oo-ui-labelElement-label'>Learn more</span><span class='oo-ui-indicatorElement-indicator oo-ui-indicatorElement-noIndicator oo-ui-image-progressive'></span></a></span><span aria-disabled='false' class='oo-ui-widget oo-ui-widget-enabled oo-ui-inputWidget oo-ui-buttonElement oo-ui-buttonElement-framed oo-ui-labelElement oo-ui-flaggedElement-primary oo-ui-flaggedElement-progressive oo-ui-buttonInputWidget'><button type='submit' tabindex='0' aria-disabled='false' name='disablecookiewarning' value='OK' class='oo-ui-inputWidget-input oo-ui-buttonElement-button'><span class='oo-ui-iconElement-icon oo-ui-iconElement-noIcon oo-ui-image-invert'></span><span class='oo-ui-labelElement-label'>Accept</span><span class='oo-ui-indicatorElement-indicator oo-ui-indicatorElement-noIndicator oo-ui-image-invert'></span></button></span></div></form></div>
</div>

					</div>
					<!-- category links -->
					<div id="catlinks" class="catlinks" data-mw="interface"><div id="mw-normal-catlinks" class="mw-normal-catlinks"><a href="/Special:Categories" title="Special:Categories">Categories</a>: <ul><li><a href="/Category:Articles" title="Category:Articles">Articles</a></li><li><a href="/Category:Glaucoma" title="Category:Glaucoma">Glaucoma</a></li><li><a href="/Category:Oncology/Pathology" title="Category:Oncology/Pathology">Oncology/Pathology</a></li></ul></div></div>
				</div>
			</div>
		</div>
	</div>
	<div class="mb-2 mt-4 footer container">
		<div class="row">
			<div class="col">
				<!-- navigation bar -->
				<nav class="p-navbar not-collapsible small mb-2" role="navigation" id="mw-navigation-hbpzyvba4b">
					<div class="navbar-nav">
					<!-- toolbox -->
					<div id="t-whatlinkshere" class="nav-item"><a href="/Special:WhatLinksHere/Glaucoma_Secondary_to_Intraocular_Tumors" title="A list of all wiki pages that link here [j]" accesskey="j" class="nav-link t-whatlinkshere">What links here</a></div>
					<div id="t-recentchangeslinked" class="nav-item"><a href="/Special:RecentChangesLinked/Glaucoma_Secondary_to_Intraocular_Tumors" rel="nofollow" title="Recent changes in pages linked from this page [k]" accesskey="k" class="nav-link t-recentchangeslinked">Related changes</a></div>
					<div id="t-specialpages" class="nav-item"><a href="/Special:SpecialPages" title="A list of all special pages [q]" accesskey="q" class="nav-link t-specialpages">Special pages</a></div>
					<div id="t-print" class="nav-item"><a href="javascript:print();" rel="alternate" title="Printable version of this page [p]" accesskey="p" class="nav-link t-print">Printable version</a></div>
					<div id="t-permalink" class="nav-item"><a href="/w/index.php?title=Glaucoma_Secondary_to_Intraocular_Tumors&amp;oldid=86663" title="Permanent link to this revision of the page" class="nav-link t-permalink">Permanent link</a></div>
					<div id="t-info" class="nav-item"><a href="/w/index.php?title=Glaucoma_Secondary_to_Intraocular_Tumors&amp;action=info" title="More information about this page" class="nav-link t-info">Page information</a></div>
					</div>
				</nav>
			</div>
		</div>
		<div class="row">
			<div class="col">
				<!-- footer links -->
				<div id="footer-info" class="footer-info">
					<!-- info -->
					<div> This page was last edited on November 17, 2022, at 17:19.</div>
					<div>This page has been accessed 51,906 times.</div>
				</div>
				<!-- places -->
				<div id="footer-places" class="footer-places">
					<div><a href="/EyeWiki:Privacy_policy" title="EyeWiki:Privacy policy">Privacy policy</a></div>
					<div><a href="/EyeWiki:About" title="EyeWiki:About">About EyeWiki</a></div>
					<div><a href="/EyeWiki:General_disclaimer" title="EyeWiki:General disclaimer">Disclaimers</a></div>
				</div>
			</div>
			<div class="col">
				<!-- footer icons -->
				<div id="footer-icons" class="justify-content-end footer-icons">
					<!-- poweredby -->
					<div><a href="https://www.mediawiki.org/"><img src="/w/resources/assets/poweredby_mediawiki_88x31.png" alt="Powered by MediaWiki" srcset="/w/resources/assets/poweredby_mediawiki_132x47.png 1.5x, /w/resources/assets/poweredby_mediawiki_176x62.png 2x" width="88" height="31" loading="lazy"/></a></div>
					<div><a href="https://www.semantic-mediawiki.org/wiki/Semantic_MediaWiki"><img src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAFgAAAAfCAMAAABUFvrSAAACJVBMVEXe3t62trbLy8vGxsbAwMDX19e6urqsrKxHcEzQ0NC2tratra2oqKixsbHd3eDFxcXe3t7U1NTa2trX19fQ0NDV1dWNjY2dnZ2UlJSUlJTS0tKUlJSWlpbR0dGenp79/f38/Pz+/v7t7e3v7+/u7u7s7Oz19fX29vb6+vr7+/vz8/Pz8/P4+fnw8PD39/gWTq/09PX6+vktX7b/sg8XT7F6mc/f5OwhVrNvkMthhsfT2+j7rQ/M1eZqjcmFotPs7e9Cb722xuFResK/zOObstnu7/Grvd3M1+mNqNY6aLoaUbEaUbZWfsTk6fE2Zrnp7O8bTq0kWLQuYcpcg8Xh5/Byk83a4eukud1/nM+6yeQkWcGwwuDxnRQyYrigttvI0+gpW7XGyttLdsBni8geVLo0Z9XlkCPb4u+QqtcfVLLo7PNHcr73phFGX6HsmBnpkxg6bNwnXcbX3er19vnr7/SVrdhuhLl+j70vVqY6Xqv0oxJVcbQhV76DjKTz9ffQ2evE0OZAbbzu7/PS1uFufrDnrGgpSZjy8/SQnMFddrKuekXSiCsgTKRaaZHejy9yang3VptNaqspWbnmliy3j2/m6OzT3e7x8fL4+v3p6uwaN2re0cifqLiLiZWYhYGYb0xXYn+5g0xwiMKYpc2BcHZmW2srRXpGWIhecKfilz4+WID2+PyosMywqbGqss1aVnLZq33p1sGklZqrp7dkfr7CpY9yg59Ud6QZAAAAH3RSTlPfBN/f39/f2wDf39vV3/7N2rrEz5D5c8ONuHaPuXXDImoxqwAABO1JREFUSMe1kQdz01gQgBXaBS4w9OtHwMFSdPKTUNxkW+61xN2Je4tLHJNOGukkAUINJTzaUIbO9fr7TpLtS44DZiC5b6Sn3dW+TysJaWz4cv9eZFPZu/+bhkakYR88WqP59u3vjxzdDCT7GpCD4qNH3sEGzOhB5MCR/4PmA8j25uZ33t0A23lxff5hZTIzOrz2Ph8qK936l7i1tT7hk8DAoHNsbeLWKjPdQcZ+qvX9tHMNXca1XBDXHtL6x2Bh0HWtuXUo8oTgC1gVpcdsdpew92PUYtjwzFq+E9mJYfXxx1x5l2/l5Vhy0DW6TuyQCZcR2hnswXJM0h+203471u5WKMIE5mDpspIIO8sZTMZiIbczY6+JCaI+/sJZ38qjP28+nQjkx/mcqGJ26rW3iKg/fYphCL1jNk5WbqXI0nBnu00RJ2j9bNRp6MmFS0SYIXLuUlQ5w22qizHr5MTyy2u/3XxVvHHlwtWVa/xTCQIIlEaMzrgswzA5P9BrAciYASqNoiNdjL8b0GYAHN3AGAEgzPSQc9UtYCeyBQAMO2G9PhhzXfp9qdifSCT6Lj788QQnrvWEuNPI2um0LW0D+m4A6E4AnIZOeq7ksQuJvi6eUXRW+8EWXsxNPhkYGJiSXr7Rd1qtVp9MXHkgIurzAkdFxjrj7cmKbN4K5v8RGxT2sJMTpwBflNHhUJgBdoUylzy3TuwIDBRi0hf9p9VtbW3qk30X7q2Je1IybZq7mLVWFKTSADXPoqi9AzVorda0kKTS6KkRbSgaR1GT1h5CObYiW1GU27yc5z6F9Fn/yTYedeLi9AIA6AbgxGIxAMPZcZeUHH9cFavVfY97FaNA/DbazRZVV89/61at2BTlg1JXiFtrYoBmRyd7p6/UP0XxaSDmy4pt0jmuh8qx6wQ2MmRz18TaJCUWO9xisUVhMMsoZZDiGHLLuXUbso2iatP/1HvhYu3n3bh6Pe/LUjZSj1NUJ8lSlNwahRRlMRjmyFDICikVn8+SacomdbZTVj+0mQSxweS1WqpiHK/Ncubs858f9idOJ/qKS1cv+RbFuIbMmHEvTbO4QeF25CxyD62nSbmJ1MUzRrpiwR0RPBJMpnCGxWVGXBn8TkarNGQHjuPrxOeWY4GY9FmxWHy19Gvv+ayYF6f8oYi7i8U93bjFkYokvbhWEFu8Og2ZxrUe3NMpc3vLhqqYpVV4XbwDQkpgoVwYKOR9N5d+eXB5vJevQA0pD7oVqi4WOj16vX6EYSA08WKvyeOZJw1cQ6rsnXOa/RYoM0Kls0zLuVoHhHAHL8YFXkwVCoE8uXhvMVCY8mW5Ci8eKkcgJ9azOl0UajNDFiUpj5JeloEqTgwd/iCUJP0sFMSejkpO96b4zl1fPuYiyd6Vs4GBmHSsJoYmLy/WeBTlis5rlJYrgjhe1s+XOXGEtHJOMl4VB2EHLauKdyG7JBLIc//uslRKkhOrcGJqyiU9z5UkOpVOwiGXSyQizRAfqlRc7Y5KJFnV6FReiWSV7xAWeQd/SOSq6qY18eVHq4vjlyazEJ73ScmJPVxJVKdF9MFwYpFIEL+ehvDOcSH8YXRsAa4XfwS7kd0tLfw7Sp7fl7xJywbYjTTVotfTb+849lEcb0K+2lMN/5o+tons+Rxp+PrQ8U3n0BcNSGPj4W+bPuX5ZLNo+uxwY+PfoLJHX1KXgyMAAAAASUVORK5CYII=" alt="Powered by Semantic MediaWiki" class="smw-footer" width="88" height="31" loading="lazy"/></a></div>
				</div>
			</div>
		</div>
	</div>
<script src="https://www.googletagmanager.com/gtag/js?id=UA-64665049-1" async=""></script><script>
window.dataLayer = window.dataLayer || [];
function gtag(){dataLayer.push(arguments);}
gtag('js', new Date());
gtag('config', 'UA-64665049-1', {});
</script>

<script>(RLQ=window.RLQ||[]).push(function(){mw.config.set({"wgPageParseReport":{"smw":{"limitreport-intext-parsertime":0.001},"limitreport":{"cputime":"0.354","walltime":"2.898","ppvisitednodes":{"value":1642,"limit":1000000},"postexpandincludesize":{"value":6501,"limit":2097152},"templateargumentsize":{"value":1462,"limit":2097152},"expansiondepth":{"value":11,"limit":40},"expensivefunctioncount":{"value":0,"limit":100},"unstrip-depth":{"value":0,"limit":20},"unstrip-size":{"value":39370,"limit":5000000},"timingprofile":["100.00%  809.819      1 Template:Article","100.00%  809.819      1 -total"," 97.59%  790.326      4 Template:Infobox_section"," 41.76%  338.174      8 Template:UserLookup","  5.63%   45.589      1 Template:Review_expired","  0.72%    5.852      1 Template:Infobox_end","  0.17%    1.337      1 Template:Get_active_contest","  0.12%    0.948      1 Template:Infobox_begin"]},"cachereport":{"timestamp":"20230306035154","ttl":86400,"transientcontent":false}}});mw.config.set({"wgBackendResponseTime":3517});});</script></body>
</html>